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A B S T R A C T
Background
This is an updated version of the original Cochrane Review, first published in Issue 1, 2003 and updated in 2015. This review is one
in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.
Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked
seizures. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become
seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.
Worldwide, carbamazepine and phenobarbitone are commonly used broad-spectrum antiepileptic drugs, suitable for most epileptic
seizure types. Carbamazepine is a current first-line treatment for partial onset seizures, and is used in the USA and Europe. Pheno-
barbitone is no longer considered a first-line treatment because of concerns over associated adverse events, particularly documented
behavioural adverse events in children treated with the drug. However, phenobarbitone is still commonly used in low- and middle-
income countries because of its low cost. No consistent differences in efficacy have been found between carbamazepine and phenobar-
bitone in individual trials; however, the confidence intervals generated by these studies are wide, and therefore, synthesising the data of
the individual trials may show differences in efficacy.
Objectives
To review the time to withdrawal, remission, and first seizure of carbamazepine compared with phenobarbitone when used as monother-
apy in people with partial onset seizures (simple or complex partial and secondarily generalised) or generalised onset tonic-clonic seizures
(with or without other generalised seizure types).
Search methods
For the latest update, we searched the following databases on 18 August 2016: the Cochrane Epilepsy Group Specialised Register, the
Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO),MEDLINE (Ovid,
from 1946), the US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov), and the World Health Organization
International Clinical Trials Registry Platform (ICTRP). Previously we also searched SCOPUS (from 1823) as an alternative to Embase,
but this is no longer necessary, because randomised controlled trials (RCTs) and quasi-RCTs in Embase are now included in CENTRAL.
We handsearched relevant journals and contacted pharmaceutical companies, original trial investigators, and experts in the field.
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Selection criteria
RCTs in children or adults with partial onset seizures or generalised onset tonic-clonic seizures with a comparison of carbamazepine
monotherapy versus phenobarbitone monotherapy.
Data collection and analysis
This was an individual participant data (IPD) review. Our primary outcome was ’time to withdrawal of allocated treatment’, and
our secondary outcomes were ’time to achieve 12-month remission’, ’time to achieve six-month remission’, ’time to first seizure post-
randomisation’, and ’adverse events’. We used Cox proportional hazards regression models to obtain study-specific estimates of hazard
ratios (HRs) with 95% confidence intervals (CIs), with the generic inverse variance method used to obtain the overall pooled HR and
95% CI.
Main results
IPD were available for 836 participants out of 1455 eligible individuals from six out of 13 trials; 57% of the potential data. For remission
outcomes, HR > 1 indicated an advantage for phenobarbitone, and for first seizure and withdrawal outcomes, HR > 1 indicated an
advantage for carbamazepine.
The main overall results (pooled HR adjusted for seizure type, 95% CI) were HR 1.50 for time to withdrawal of allocated treatment
(95% CI 1.15 to 1.95; P = 0.003); HR 0.93 for time to achieve 12-month remission (95% CI 0.72 to 1.20; P = 0.57); HR 0.99 for time
to achieve six-month remission (95% CI 0.80 to 1.23; P = 0.95); and HR 0.87 for time to first seizure (95% CI 0.72 to 1.06; P = 0.18).
Results suggest an advantage for carbamazepine over phenobarbitone in terms of time to treatment withdrawal and no statistically
significant evidence between the drugs for the other outcomes. We found evidence of a statistically significant interaction between
treatment effect and seizure type for time to first seizure recurrence (Chi² test for subgroup differences P = 0.03), where phenobarbitone
was favoured for partial onset seizures (HR 0.76, 95% CI 0.60 to 0.96; P = 0.02) and carbamazepine was favoured for generalised onset
seizures (HR 1.23, 95% CI 0.88 to 1.77; P = 0.27). We found no evidence of an interaction between treatment effect and seizure type
for the other outcomes. However, methodological quality of the included studies was variable, with 10 out of the 13 included studies
(4 out of 6 studies contributing IPD) judged at high risk of bias for at least one methodological aspect, leading to variable individual
study results, and therefore, heterogeneity in the analyses of this review. We conducted sensitivity analyses to examine the impact of
poor methodological aspects, where possible.
Authors’ conclusions
Overall, we found evidence suggestive of an advantage for carbamazepine in terms of drug effectiveness compared with phenobarbitone
(retention of the drug in terms of seizure control and adverse events) and evidence suggestive of an association between treatment
effect and seizure type for time to first seizure recurrence (phenobarbitone favoured for partial seizures and carbamazepine favoured
for generalised seizures). However, this evidence was judged to be of low quality due to poor methodological quality and the potential
impact on individual study results (and therefore variability (heterogeneity) present in the analysis within this review), we encourage
caution when interpreting the results of this review and do not advocate that the results of this review alone should be used in choosing
between carbamazepine and phenobarbitone. We recommend that future trials should be designed to the highest quality possible with
considerations for allocation concealment and masking, choice of population, choice of outcomes and analysis, and presentation of
results.
P L A I N L A N G U A G E S U M M A R Y
Title: Carbamazepine versus phenobarbitone monotherapy (single drug treatment) for epilepsy
Background
Epilepsy is a common neurological disorder in which abnormal electrical discharges from the brain cause recurrent seizures. We studied
two types of epileptic seizures in this review: generalised onset seizures in which electrical discharges begin in one part of the brain and
move throughout the brain, and partial onset seizures in which the seizure is generated in and affects one part of the brain (the whole
hemisphere of the brain or part of a lobe of the brain).
For around 70% of people with epilepsy, a single antiepileptic drug can control generalised onset or partial onset seizures. Worldwide,
phenobarbitone and carbamazepine are commonly used antiepileptic drugs; however, carbamazepine is used more commonly in the
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USA and Europe because of concerns over side-effects associated with phenobarbitone, particularly concerns over behavioural changes
in children treated with phenobarbitone. Phenobarbitone is still commonly used in developing countries in Africa, Asia, and South
America because of the low cost of the drug.
Review methods
In this review, we evaluated the evidence from 13 randomised controlled clinical trials comparing phenobarbitone with carbamazepine
based on how effective the drugs were at controlling seizures (i.e. whether people had recurrence of seizures or had long periods of
freedom from seizures (remission)) and how tolerable any related side-effects of the drugs were. We were able to combine data for 836
people from six of the 13 trials; for the remaining 619 people from seven trials, data were not available to use in this review.
Key results
Results of the review suggest that people are more likely to withdraw from phenobarbitone treatment earlier than from carbamazepine
treatment, because of seizure recurrence, side-effects of the drug, or both. Results also suggest that recurrence of seizures after starting
treatment with phenobarbitone may happen earlier than treatment with carbamazepine for people with generalised seizures, but vice-
versa for people with partial onset seizures. We found no difference between carbamazepine and phenobarbitone for people achieving
long periods of seizure freedom (six- or 12-month remission of seizures).
Conclusions
We recommend that the results of this review are interpreted with caution as we were unable to combine the data for all people treated
in trials comparing carbamazepine or phenobarbitone. Also, for four of the six trials used in our results, we found at least one problem
in the design of the trial, which may have impacted upon the quality of the results of the individual trials, and therefore our results
from combining trial data. We judge that the quality of the evidence in this review is low and we do not recommend using the results
of this review alone for making a choice between carbamazepine or phenobarbitone for the treatment of epilepsy. We recommend that
all future trials comparing these drugs or any other antiepileptic drugs should be designed using high quality methods to ensure results
are also of high quality.
How up-to-date is this review?
The review authors searched for studies that had been published up to August 2016.
3Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Carbamazepine compared with phenobarbitone for epilepsy
Patient or population: adults and children with newly onset part ial or generalised epilepsy
Settings: outpat ients
Intervention: carbamazepine
Comparison: phenobarbitone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)¹
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenobarbitone Carbamazepine
Time to withdrawal of
allocated treatment -
all participants, strati-
fied by epilepsy type
Range of follow-up (all
part icipants): 0 to 4653
days
390 per 1000 281 per 1000
(224 to 350)
HR 1.50 (1.15 to 1.95) 676
(4 studies)
⊕⊕©©
low2,3
HR > 1 indicates a
clinical advantage for
carbamazepine
Time to withdrawal of
allocated treatment
Subgroup: generalised
onset seizures
Range of follow-up (all
part icipants): 0 to 4653
days
286 per 1000 197 per 1000
(110 to 340)
HR 1.53 (0.81 to 2.88) 156
(3 studies)
⊕⊕©©
low2,3
HR > 1 indicates a
clinical advantage for
carbamazepine
Time to withdrawal of
allocated treatment
Subgroup: partial on-
set seizures
Range of follow-up (all
part icipants): 0 to 4272
420 per 1000 307 per 1000
(239 to 385)
HR 1.49 (1.12 to 2.00) 520
(4 studies)
⊕⊕©©
low2,3
HR > 1 indicates a
clinical advantage for
carbamazepine
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The assumed risk is calculated as the event rate in the
phenobarbitone treatment group. The corresponding risk in the carbamazepine treatment group (and its 95% CI) is based on the assumed risk in the comparison group and
the relat ive ef fect of the intervent ion (and its 95% CI).
The corresponding risk is calculated as the assumed risk x the relat ive risk of the intervent ion where relat ive risk = (1 - exp(HR x ln(1 - assumed risk)) )/ assumed risk.
CI: conf idence interval; RR: risk rat io; HR: hazard rat io; exp: exponent ial.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Pooled HR for all part icipants adjusted for seizure type.
2There was high risk of bias for at least one element of three studies included in the analysis; de Silva 1996 and Heller 1995
were open-label, and the lack of masking may have inf luenced the withdrawal rates in the study. Placencia 1993 did not
adequately conceal allocat ion for all part icipants, which may have inf luenced the withdrawal rates in the study. There were
inconsistencies in Placencia 1993 between published data and IPD, which the authors could not resolve.
3Substant ial heterogeneity was present between studies; sensit ivity analyses showed that Placencia 1993 contributed the
largest amount of variability to analysis.
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B A C K G R O U N D
This is an updated version of the original Cochrane Review, first
published in Issue 1, 2003 (Tudur Smith 2003), and updated in
2015.
Description of the condition
Epilepsy is a common neurological condition in which abnormal
electrical discharges from the brain cause recurrent unprovoked
seizures. Epilepsy is a disorder of many heterogenous seizure types,
with an estimated incidence of 33 to 57 per 100,000 person-
years worldwide (Annegers 1999; Hirtz 2007; MacDonald 2000;
Olafsson 2005; Sander 1996), accounting for approximately 1%
of the global burden of disease (Murray 1994).
The lifetime risk of epilepsy onset is estimated to be 1300 to
4000 per 100,000 person-years (Hauser 1993; Juul-Jenson 1983),
and the lifetime prevalence could be as large as 70 million people
worldwide (Ngugi 2010). It is believed that with effective drug
treatment, up to 70% of individuals with active epilepsy have the
potential to go into long-term remission shortly after starting drug
therapy (Cockerell 1995; Hauser 1993; Sander 2004), and around
70% of individuals can achieve seizure freedom using a single
antiepileptic drug in monotherapy (Cockerell 1995). Current Na-
tional Institute for Health and Care Excellence (NICE) guidelines
recommend that both adults and children with epilepsy should be
treated with monotherapy, wherever possible (NICE 2012). The
remaining 30% of individuals experience refractory or drug-re-
sistant seizures, which often require treatment with combinations
of antiepileptic drugs or alternative treatments, such as epilepsy
surgery (Kwan 2000).
We studied two seizure types in this review: generalised onset
seizures in which electrical discharges begin in one part of the
brain and move throughout the brain, and partial onset seizures in
which the seizure is generated in and affects one part of the brain
(the whole hemisphere of the brain or part of a lobe of the brain).
Description of the intervention
Carbamazepine and phenobarbitone are among the most com-
monly used and earliest drugs licensed for the treatment of epilep-
tic seizures; phenobarbitone has been used as monotherapy for
partial seizures and generalised tonic-clonic seizures for over 50
years (Gruber 1962), and carbamazepine, for over 30 years (Shakir
1980). Current NICE guidelines for adults and children recom-
mend carbamazepine as a first-line treatment for partial onset
seizures and as a second-line treatment for generalised tonic-clonic
seizures if first-line treatments, sodium valproate and lamotrigine,
are deemed unsuitable (NICE 2012). However, there is evidence
that carbamazepine may exacerbate some other generalised seizure
types, such as myoclonic and absence seizures (Liporace 1994;
Shields 1983; Snead 1985).
Phenobarbitone is no longer considered a first-line treatment in the
USA andmost of Europe because of concerns over short- and long-
term tolerability (Wallace 1997); particularly in children, there is
concern about behavioural disturbance caused by phenobarbitone
(Trimble 1988). One open-label paediatric study in the UK, de
Silva 1996, withdrew the phenobarbitone arm of the trial because
of concerns about behavioural problems and difficulties getting
paediatricians to randomise individuals. However, the largest re-
ported randomised controlled trial (RCT) investigating pheno-
barbitone as monotherapy in adults with partial seizures, Mattson
1985, did not find phenobarbitone to be more associated with
adverse events than other study drugs (carbamazepine, phenytoin,
and primidone). In fact, phenobarbitone was significantly associ-
ated with the lowest incidence of motor disturbances (ataxia (lack
of voluntary co-ordination of muscle movements), incoordina-
tion, nystagmus, and tremor) and gastrointestinal problems.
Phenobarbitone is still used as a first-line drug in low- and mid-
dle-income countries (Banu 2007; Ogunrin 2005; Pal 1998).
Two paediatric trials conducted in Bangladesh (Banu 2007), and
rural India (Pal 1998), comparing phenobarbitone with carba-
mazepine and phenytoin, respectively, found no excess in be-
havioural side-effects from phenobarbitone, but a trial in Nige-
rian adults (Ogunrin 2005), showed evidence of an association be-
tween phenobarbitone and worsening of cognitive impairments,
particularly memory deficits.
Both carbamazepine and phenobarbitone have been shown to have
teratogenic (disturbances to foetal development) effects, where the
risk is estimated to be two to three times that of the general popu-
lation (Meador 2008;Morrow 2006); carbamazepine is associated
particularly with neural tube defects (Matlow 2012), and pheno-
barbitone is associated with low folic acid levels and megaloblastic
anaemia (anaemia characterised by many large immature and dys-
functional red blood cells; Meador 2008). In addition to concerns
over behavioural and cognitive adverse events, phenobarbitone is
commonly associated with somnolence (sedation) and connective
tissue abnormalities, such as Dupuytren’s contracture and frozen
shoulder (Baulac 2002).
How the intervention might work
Antiepileptic drugs suppress seizures by reducing neuronal ex-
citability (MacDonald 1995). Phenobarbitone and carbamazepine
are broad-spectrum treatments suitable for many seizure types,
and both have an anticonvulsant mechanism through block-
ing ion channels, binding with neurotransmitter receptors, or
through inhibiting the metabolism or reuptake of neurotransmit-
ters (Ragsdale 1991), and the modulation of gamma-aminobu-
tyric acid-A (GABA-A) receptors (Rho 1996).
Why it is important to do this review
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The aim of this review was to summarise efficacy and tolerability
data from existing trials comparing carbamazepine and phenobar-
bitone when used as monotherapy treatments. The adverse event
profiles of the two drugs are well documented (see example ref-
erences from Description of the intervention), and the largest re-
ported RCT investigating carbamazepine and phenobarbitone as
monotherapy in adults with partial seizures, Mattson 1985, found
carbamazepine to be significantly better at controlling seizures
than phenobarbitone, but other trials, including trials recruiting
individuals with generalised onset seizures, have found no differ-
ences in efficacy between the two drugs (Banu 2007; Bidabadi
2009; Cereghino 1974; Chen 1996; Cossu 1984; Czapinski 1997;
de Silva 1996; Feksi 1991; Heller 1995; Mitchell 1987; Ogunrin
2005; Placencia 1993). Although individual studies have found
no consistent differences in efficacy, the confidence intervals gen-
erated by these studies are wide, and they have not excluded im-
portant differences in efficacy, which synthesising the data of the
individual trials may show.
There are difficulties in undertaking a review of epilepsy
monotherapy trials, as the important efficacy outcomes require
analysis of time-to-event data (for example, time to first seizure
after randomisation). Although methods have been developed
to synthesise time-to-event data using summary information
(Parmar 1998;Williamson 2002), the appropriate statistics are not
commonly reported in published epilepsy trials (Nolan 2013a).
Furthermore, although most epilepsy monotherapy trials collect
seizure data, there has been no uniformity in the definition and
reporting of outcomes. For example, trials may report time to 12-
month remission but not time to first seizure or vice versa, or some
trials may define time to first seizure from the date of randomi-
sation while others use the date of achieving maintenance dose.
Trial investigators have also adopted differing approaches to the
analysis, particularly with respect to the censoring of time-to-event
data. For these reasons, we performed this review using individual
participant data (IPD), which helps to overcome these problems.
This review is one in a series of Cochrane IPD Reviews investi-
gating pair-wise monotherapy comparisons. These data have also
been included in a network meta-analysis (Tudur Smith 2007),
undertaken following a previous version of this review.
O B J E C T I V E S
To review the time to withdrawal, remission, and first seizure
of carbamazepine compared with phenobarbitone when used as
monotherapy in people with partial onset seizures (simple or com-
plex partial and secondarily generalised) or generalised onset tonic-
clonic seizures (with or without other generalised seizure types).
M E T H O D S
Criteria for considering studies for this review
Types of studies
1. Randomised controlled trials (RCTs) using either an
adequate method of allocation concealment (e.g. sealed opaque
envelopes) or a ’quasi’ method of randomisation (e.g. allocation
by date of birth).
2. Studies may have been double-blind, single-blind, or
unblinded.
3. Studies must have included a comparison of carbamazepine
monotherapy with phenobarbitone monotherapy in individuals
with epilepsy.
Types of participants
1. Children or adults with partial onset seizures (simple
partial, complex partial, or secondarily generalised tonic-clonic
seizures) or generalised onset tonic-clonic seizures (with or
without other generalised seizure types).
2. Individuals with a new diagnosis of epilepsy or who had a
relapse following antiepileptic monotherapy withdrawal.
Types of interventions
Carbamazepine or phenobarbitone as monotherapy.
Types of outcome measures
Below is a list of outcomes investigated in this review. Reporting
of these outcomes in the original trial report was not an eligibility
requirement for this review.
Primary outcomes
1. Time to withdrawal of allocated treatment (retention time).
This was a combined outcome reflecting both efficacy and
tolerability, as the following may have caused withdrawal of
treatment: continued seizures, side-effects, non-compliance, or
the initiation of additional add-on treatment (i.e. allocated
treatment had failed). This is an outcome to which the
participant makes a contribution and is the primary outcome
measure recommended by the Commission on Antiepileptic
Drugs of the International League Against Epilepsy (ILAE 1998;
ILAE 2006).
Secondary outcomes
1. Time to achieve 12-month remission (seizure-free period).
2. Time to achieve six-month remission (seizure-free period).
3. Time to first seizure post-randomisation.
4. Adverse events (all reported whether related or unrelated to
treatment).
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Search methods for identification of studies
Electronic searches
Searches were run for the original review in 2003 and subsequent
searches were run in October 2013 and September 2014. For the
latest update we searched the following databases on 18 August
2016, with no language restrictions.
• The Cochrane Epilepsy Group Specialised Register using
the search strategy outlined in Appendix 1.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online
(CRSO) using the search strategy outlined in Appendix 2.
• MEDLINE Ovid (1946 to 18 August 2016) using the
search strategy outlined in Appendix 3.
• The US National Institutes of Health Ongoing Trials
Register using the search terms ’carbamazepine and
phenobarbital and epilepsy’ (ClinicalTrials.gov).
• The World Health Organization International Clinical
Trials Registry Platform using the search terms ’carbamazepine
and phenobarbital and epilepsy’ (ICTRP).
Previously we also searched SCOPUS (1823 to 18 September
2014) as an alternative to Embase, using the search strategy out-
lined in Appendix 4, but this is no longer necessary, because ran-
domised and quasi-RCTs in Embase are now included in CEN-
TRAL.
Searching other resources
In addition, we handsearched relevant journals, reviewed the ref-
erence lists of retrieved studies to search for additional reports of
relevant studies, and contacted Novartis (manufacturers of carba-
mazepine), and experts in the field for information of any ongoing
studies, as well as original investigators of relevant trials found.
Data collection and analysis
Selection of studies
Two review authors (SJN and AGM) independently assessed trials
for inclusion, resolving any disagreements by mutual discussion.
Data extraction and management
We requested the following IPD for all trials meeting our inclusion
criteria.
• Trial methods
◦ method of generation of random list
◦ method of concealment of randomisation
◦ stratification factors
◦ blinding methods
• Participant covariates
◦ gender
◦ age
◦ seizure types
◦ time between first seizure and randomisation
◦ number of seizures prior to randomisation (with dates)
◦ presence of neurological signs
◦ electroencephalographic (EEG) results
◦ computerised tomography/magnetic resonance
imaging (CT/MRI) results
• Follow-up data
◦ treatment allocation
◦ date of randomisation
◦ dates of follow-up
◦ dates of seizures post-randomisation or seizure
frequency data between follow-up visits
◦ dates of treatment withdrawal and reasons for
treatment withdrawal
◦ dose
◦ dates of dose changes
For each trial for which we did not obtain IPD, we carried out
an assessment to see whether any relevant aggregate level data had
been reported or could be indirectly estimated using the methods
of Parmar 1998 and Williamson 2002.
Three studies involving 804 participants, provided seizure data in
terms of the number of seizures recorded between each follow-up
visit rather than specific dates of seizures (Feksi 1991; Mattson
1985; Placencia 1993). To enable the calculation of time-to-event
outcomes, we applied linear interpolation to approximate dates
of seizures between follow-up visits. For example, if the study
recorded four seizures between two visits that occurred on 1March
1990 and 1 May 1990 (interval of 61 days), then the date of first
seizure would be approximately 13 March 1990. This allowed the
computation of an estimate of the time to six-month remission,
12-month remission, and first seizure.
We calculated time to six-month and 12-month remission from
the date of randomisation to the date (or estimated date) that the
individual had first been free of seizures for six or 12 months,
respectively. If the person had one or more seizures in the titration
period, a six-month or 12-month seizure-free period could also
occur between the estimated date of the last seizure in the titration
period and the estimated date of the first seizure in themaintenance
period.
We calculated time to first seizure from the date of randomisation
to the date that we estimated their first seizure to have occurred. If
seizure data were missing for a particular visit, we censored these
outcomes at the previous visit. We also censored these outcomes if
the individual died or if follow-up ceased prior to the occurrence of
the event of interest. We used these methods in the remaining four
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trials involving 326 participants (Banu 2007; de Silva 1996; Heller
1995; Ogunrin 2005), for which we directly received outcome
data (dates of seizures after randomisation).
In the Ogunrin 2005 trial, all 37 participants completed the 12-
week trial duration without withdrawing from the study. For four
trials (685 participants), we extracted dates and reason for treat-
ment withdrawal from trial case report forms for the original re-
view (de Silva 1996; Heller 1995;Mattson 1985; Placencia 1993).
Two review authors independently extracted data from all case
report forms, resolving disagreements by reconsidering the case
report forms at conference. For the analysis of time-to-event, we
defined an ’event’ as either the withdrawal of the allocated treat-
ment because of poor seizure control, adverse events, or both. We
also classed non-compliance with the treatment regimen or the
addition of another antiepileptic drug as ’events’. We censored
the outcome if treatment was withdrawn because the individual
achieved a period of remission or if the individual was still on
allocated treatment at the end of follow-up. The Banu 2007 trial
(108 participants), provided the reason for withdrawal of allocated
treatment and date of last follow-up visit. Withdrawal of allocated
treatment did not always coincide with date of last follow-up visit
(i.e. several participants had the allocated treatment substituted
for the other trial drug and continued to be followed up). Dates of
withdrawal of allocated treatment could not be provided; there-
fore, we could not include participants from this trial in the out-
come ’time to withdrawal of allocated treatment’.
Assessment of risk of bias in included studies
Two review authors (SJN and JW) independently assessed all in-
cluded studies for risk of bias according to the Cochrane Risk of
Bias tool (Higgins 2011), resolving any disagreements by discus-
sion.
Measures of treatment effect
We measured all outcomes in this review as time-to-event out-
comes with the hazard ratio (HR) used as the measure of treat-
ment effect. We calculated outcomes from IPD provided, where
possible, or extracted from published studies.
Unit of analysis issues
We did not have any unit of analysis issues. The unit of allocation
and analysis was individual for all included studies, and no studies
included in meta-analysis were of a repeated measures (longitudi-
nal) nature or of a cross-over design.
Dealing with missing data
For each trial that supplied IPD, we reproduced results from trial
results where possible and performed consistency checks.
• We cross-checked trial details against any published report
of the trial and contacted original trial authors if we found
missing data, errors, or inconsistencies.
• If study authors could not resolve inconsistencies between
IPD and published data, depending on the extent of the
inconsistencies, we performed sensitivity analysis (see Sensitivity
analysis) or excluded the data from the meta-analysis.
• We reviewed the chronological randomisation sequence and
checked the balance of prognostic factors, taking account of
factors stratified for in the randomisation procedure.
Assessment of heterogeneity
We assessed heterogeneity statistically using the Q test (P < 0.10
for significance) and the I² statistic (greater than 50% indicating
considerable heterogeneity; Higgins 2003), output produced us-
ing the generic inverse variance approach in Data and analyses,
and visually by inspecting forest plots.
Assessment of reporting biases
Two review authors (SJN and JW) undertook all full quality and
’Risk of bias’ assessments. In theory, a review using IPD should
overcome issues of reporting biases, as unpublished data can be
provided and unpublished outcomes calculated. Any selective re-
porting bias detected could be assessed with the Outcome Report-
ing Bias In Trials (ORBIT) classification system (Kirkham 2010).
Data synthesis
We carried out our analysis on an intention-to-treat basis (that
is, we analysed participants in the group to which they were ran-
domised, irrespective of which treatment they actually received).
Therefore, for the time-to-event outcomes ’time to six-month re-
mission’, ’time to 12-month remission’, and ’time to first seizure
post-randomisation’, we did not censor participants if treatment
was withdrawn.
For all outcomes, we investigated the relationship between the
time-to-event and treatment effect of the antiepileptic drugs. We
used Cox proportional hazards regression models to obtain study-
specific estimates of log (HR) or treatment effect and associated
standard errors in statistical SAS software, version 9.2.The model
assumes that the ratio of hazards (risks) between the two treatment
groups is constant over time (i.e. hazards are proportional). We
tested this proportional hazards assumption of the Cox regression
model for each outcome of each study by testing the statistical sig-
nificance of a time-varying covariate in the model. We evaluated
overall estimates of HRs (with 95% confidence intervals (CIs))
using the generic inverse variance method in MetaView. We ex-
pressed results as a HR and a 95% CI.
By convention, a HR greater than 1 indicates that an event is more
likely to occur earlier on carbamazepine than on phenobarbitone.
Hence, for time to withdrawal of allocated treatment or time to
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first seizure, a HR greater than 1 indicates a clinical advantage for
phenobarbitone (e.g. a HR of 1.2 would suggest a 20% increase in
risk of withdrawal from carbamazepine compared with phenobar-
bitone), and for time to six-month and 12-month remission, aHR
greater than 1 indicates a clinical advantage for carbamazepine.
Subgroup analysis and investigation of heterogeneity
Because of the strong clinical belief that some antiepileptic
drugs are more effective in some seizure types than others (see
Description of the intervention and How the intervention might
work), we stratified all analyses by seizure type (partial onset versus
generalised onset), according to the classification of main seizure
type at baseline. We classified partial seizures (simple or complex)
and partial secondarily generalised seizures as partial epilepsy.
We classified primarily generalised seizures as generalised epilepsy.
We conducted a Chi² test of interaction between treatment and
epilepsy type. If we found significant statistical heterogeneity to be
present, we performedmeta-analysis with a random-effects model
in addition to a fixed-effect model, presenting the results of both
models and performing sensitivity analyses to investigate differ-
ences in study characteristics.
Sensitivity analysis
We performed several sensitivity analyses to test the robustness of
our results to characteristics of the included studies.
1. Placencia 1993 concealed allocation via opaque sealed
envelopes; however, the trial did not use this method for all trial
participants. As inadequate allocation concealment could lead to
biased selection of participants, we performed sensitivity analysis
excluding data from Placencia 1993 for each outcome and
observed any change to results and conclusions.
2. Following consistency checks of IPD for Placencia 1993
and Banu 2007, we found some inconsistencies between the data
provided and the results in the publications in terms of
withdrawal and seizure recurrences, respectively. Therefore, we
performed sensitivity analyses for outcomes ’time to withdrawal
of allocated treatment’ and ’time to first seizure’, respectively, to
investigate any impact of these inconsistencies on our results. For
Placencia 1993, we compared reason for withdrawal in the data
provided with reasons reported in the publication and performed
a sensitivity analysis of those withdrawals that we classed as
’events’ or ’censored observations’ (see Effects of interventions for
further details). Regarding Banu 2007, we did not have sufficient
information to examine the classification of participants as
’events’ and ’censored observations’ in the analysis of ’time to first
seizure’; therefore, we performed a simple sensitivity analysis
excluding data from Banu 2007 from the outcome of ’time to
first seizure’ and observed any change to results and conclusions.
3. de Silva 1996 withdrew the phenobarbitone arm of the trial
after 10 children were randomised to phenobarbitone due to
concerns over unacceptable side-effects. The trial did not
randomise any further children to phenobarbitone and
continued with the three other treatment arms: carbamazepine,
phenytoin, and sodium valproate. For the primary and
secondary outcomes of this review, we included all children
randomised to carbamazepine (n = 54) and phenobarbitone (n =
10) from de Silva 1996, and to account for the imbalance
between children randomised to the two drugs on this trial, we
performed sensitivity analysis including only those children who
were randomised before the withdrawal of the phenobarbitone
arm from the trial. For sensitivity analysis, we analysed 20
children (10 males and 10 females), 10 randomised to each drug,
nine with generalised seizures and 11 with partial seizures. We
performed this sensitivity analysis for each outcome and
observed any change to results and conclusions.
4. Misclassification of seizure type is a recognised problem in
epilepsy; whereby, some people with generalised seizures have
been mistakenly classed as having partial onset seizures and vice
versa. There is clinical evidence that individuals with generalised
onset seizures are unlikely to have an ’age of onset’ greater than
25 to 30 years (Malafosse 1994). Such misclassification impacted
upon the results of a review in our series of pair-wise reviews for
monotherapy in epilepsy comparing phenytoin with sodium
valproate, in which nearly 50% of participants analysed may
have had their seizure type misclassified (Nolan 2013b). Given
the overlap of studies contributing to this review and the
phenytoin versus sodium valproate review, we suspected that
misclassification of seizure type could also be likely in this review,
so we examined the distribution of age at onset for individuals
with generalised seizures.
Banu 2007 and de Silva 1996 were paediatric studies, andMattson
1985 recruited participants with partial seizures only, so there were
no participants with new onset generalised seizures over the age of
30 in these studies.
Twenty-two out of 70 individuals (31%) with generalised onset
seizures were over the age of 30 in Heller 1995, 19 out of 30
individuals (63%) with generalised onset seizures were over the age
of 30 in Ogunrin 2005, and 24 out of 59 individuals (41%) with
generalised onset seizureswere over the age of 30 inPlacencia 1993.
Therefore, out of 245 participants from the six studies providing
IPD, 65 (27%) may have been wrongly classified as having new
onset generalised seizures.
To investigate misclassification for each outcome, we reclassified
the 65 individuals with generalised seizure types and age at onset
greater than 30 into an ’uncertain seizure type’ group and re-anal-
ysed three subgroups (partial onset, generalised onset, uncertain
seizure type).
’Summary of findings’ tables and quality of the
evidence (GRADE)
For the 2016 update, we have added two ’Summary of findings’
tables to the review (outcomes in the tables decided before the
update started based on clinical relevance).
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Summary of findings for themain comparison reports the primary
outcome of ’time to treatment withdrawal’ in the subgroups of
participants with partial onset seizures, generalised onset seizures,
and overall, adjusted by epilepsy type.
Summary of findings 2 reports the secondary outcomes of ’time to
12-month remission’ and ’time to first seizure’ in the subgroups of
participants with partial onset seizures, generalised onset seizures,
and overall, adjusted by epilepsy type.
We determined the quality of the evidence using the GRADE ap-
proach (Atkins 2004), where we downgraded evidence in the pres-
ence of high risk of bias in at least one trial, indirectness of the evi-
dence, unexplained heterogeneity or inconsistency, imprecision of
results, and high probability of publication bias. We downgraded
evidence by one level if the limitation was considered serious and
two levels if considered very serious, as judged by the review au-
thors. Under the GRADE approach, evidence may also be up-
graded if a large treatment effect is demonstrated with no obvious
biases or if a dose-response effect exists.
R E S U L T S
Description of studies
Results of the search
We identified 267 records from the databases and search strategies
outlined in Electronic searches. We found one further record by
searching other resources (handsearching). We removed 98 du-
plicate records and screened 170 records (title and abstract) for
inclusion in the review.
We excluded 148 records based on the title and abstract and as-
sessed 22 full-text articles for inclusion in the review. We excluded
nine studies (see Excluded studies below) and included 13 studies
in the review (see Included studies).
Following an updated search in August 2016, we identified 123
records fromElectronic searches.We removed 35 duplicate records
and screened 88 records (title and abstract) for inclusion in the
review. All 88 records were clearly irrelevant and excluded.
See Figure 1 for a PRISMA study flow diagram (Moher 2009).
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Figure 1. Study flow diagram.
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Included studies
We included 13 trials in this review (Banu 2007; Bidabadi 2009;
Cereghino 1974; Chen 1996; Cossu 1984; Czapinski 1997; de
Silva 1996; Feksi 1991; Heller 1995; Mattson 1985; Mitchell
1987; Ogunrin 2005; Placencia 1993). Two included studies were
available in abstract form only (Bidabadi 2009; Czapinski 1997),
and one included study was published in Italian, which we trans-
lated into English (Cossu 1984).
Two trials recruited individuals of all ages (Feksi 1991; Placencia
1993); five trials recruited children only (de Silva 1996 defined
children as under the age of 16, Banu 2007 andChen 1996 defined
children as under the age of 15, and Bidabadi 2009 and Mitchell
1987 defined children as under the age of 12), and the remain-
ing six trials recruited adults only. Of the adults-only trials, three
defined adults to be individuals above the age of 18 (Cereghino
1974; Czapinski 1997; Mattson 1985), one trial classed adults as
older than 13 years (Heller 1995), one trial classed adults as older
than 14 years (Ogunrin 2005), and one trial classed adults as older
than 15 years (Cossu 1984). Seven trials recruited individuals with
partial onset seizures and generalised onset seizures (Banu 2007;
Chen 1996; de Silva 1996; Feksi 1991; Heller 1995; Ogunrin
2005; Placencia 1993), three trials recruited individuals with par-
tial onset seizures only (Cereghino 1974; Mattson 1985; Mitchell
1987), one trial recruited individuals with partial seizures and sec-
ondarily generalised seizures (Bidabadi 2009), one trial recruited
individuals with complex partial seizures only (Czapinski 1997),
and one trial recruited individuals with temporal lobe epilepsy
only (Cossu 1984).
Ten trials recruited individuals with new onset seizures, or previ-
ously untreated seizures, or both (Banu 2007; Chen 1996; Cossu
1984; Czapinski 1997; de Silva 1996; Feksi 1991; Heller 1995;
Mitchell 1987; Ogunrin 2005; Placencia 1993); one trial re-
cruited institutionalised participants with uncontrolled seizures
(Cereghino 1974); one trial recruited “previously untreated or un-
der-treated” individuals (Mattson 1985); and one trial (reported
only in abstract form) provided no information regarding new on-
set of seizures in participants (Bidabadi 2009).
Five trials were conducted in Europe (Bidabadi 2009; Cossu 1984;
Czapinski 1997; de Silva 1996; Heller 1995); three trials were
conducted in the USA (Cereghino 1974; Mattson 1985; Mitchell
1987); one trial was conducted in Taiwan (Chen 1996); and four
trials were conducted in rural areas or developing countries, or
both: one trial in Nigeria (Ogunrin 2005), one trial in Bangladesh
(Banu 2007), one trial in Kenya (Feksi 1991), and one trial in
Ecuador (Placencia 1993).
We did not obtain individual participant data (IPD) for six trials,
with a total of 317 participants, as suitable seizure data for the
outcomes examined in this review were not recorded (Chen 1996;
Mitchell 1987), the trial authors no longer had a copy of the data
(Cereghino 1974), or trial authors did not respond to our data
requests (Bidabadi 2009; Cossu 1984; Czapinski 1997). A further
trial, which randomised 302 participants (Feksi 1991), provided
access to an IPD dataset, but this was not the final dataset used for
the analysis published by the original authors. The pharmaceu-
tical company that sponsored the trial, Ciba-Geigy, who at that
time held the product license for carbamazepine, held the final
dataset. Since the trial was undertaken, there have been a num-
ber of mergers and restructures within the industry, and the cur-
rent owners of the data are Novartis. Unfortunately, Novartis were
unable to locate the data for this trial. The dataset that we had
for this trial contained a number of problems and inconsistencies,
and we therefore decided not to include this trial in the meta-
analysis. None of these seven trials reported the specific time-to-
event outcomes chosen for this review, and we could not extract
sufficient aggregate data from the trial publications in any other
trial. Therefore, we could not include them in data synthesis. Table
1 contains full details of outcomes considered and summaries of
results in each eligible trial for which IPD were not available.
IPD were available for the remaining six trials, which recruited a
total of 836 participants, representing 57% of 1455 individuals
from all 13 identified eligible trials. Four trials provided comput-
erised data directly (Banu 2007; Mattson 1985; Ogunrin 2005;
Placencia 1993), and the authors of two trials (de Silva 1996;
Heller 1995), supplied a combination of both computerised and
hard copy data (although mostly computerised).
Data were available for the following participant characteristics
(percentage of 836participantswith data available): sex (99%, data
missing for 6 participants in de Silva 1996 and 4 participants in
Mattson 1985); seizure type (100%); drug randomised (99%, data
missing for 6 participants in de Silva 1996); age at randomisation
(99%, data missing for 1 participant inHeller 1995, 6 participants
in de Silva 1996, and 5 participants in Mattson 1985); number of
seizures in six months prior to randomisation (98%, data missing
for 5 participants from Banu 2007, 1 participant in Heller 1995,
6 participants in de Silva 1996, and 7 participants in Mattson
1985); and time since first seizure to randomisation (94%, data
missing for 2 participants inHeller 1995, 6 participants in de Silva
1996, 5 participants in Mattson 1985, and all 37 participants in
Ogunrin 2005).
Three trials provided the results of neurological examinations for
220 participants (27%) (de Silva 1996; Heller 1995; Ogunrin
2005). Three trials provided electroencephalographic (EEG) re-
sults for 600 participants (72%) (103 participants from Banu
2007, 305 participants from Mattson 1985, and all participants
from Placencia 1993). Two trials provided computerised tomogra-
phy/magnetic resonance imaging (CT/MRI) results for 304partic-
ipants (36%) (26 from Banu 2007 and 278 fromMattson 1985).
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See the ’Characteristics of included studies’ tables for a detailed
description of each study included in this review.
Excluded studies
We excluded two duplicate trials (Cereghino 1973; Smith 1987),
and we retained the most relevant primary reference for each trial
in the review (Cereghino 1974 and Mattson 1985, respectively).
We excluded five studies that were not randomised controlled trials
(RCTs) (Bird 1966; Castro-Gago 1998; Hansen 1980; Kuzuya
1993; Sabers 1995), and we excluded two trials that did not use
carbamazepine and phenobarbitone monotherapy (Marjerrison
1968; Meador 1990). See the ’Characteristics of excluded studies’
tables for further details.
Risk of bias in included studies
For further details, see the ’Characteristics of included studies’
tables, Figure 2, and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study
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Allocation
(1) Trials for which we received individual participant data
(IPD)
Three trials reported adequate methods of randomisation and al-
location concealment and we judged all three to be at low risk of
bias: two trials used permuted blocks to generate a random list and
concealed allocation by using sealed opaque envelopes (de Silva
1996; Heller 1995); and one trial used number tables to generate a
random list and concealed allocation by allocating the randomised
drug on a different site to where participants were randomised
(Ogunrin 2005). One trial reported only that participants were
randomised with stratification for seizure type (Mattson 1985); no
further information was provided in the study publication or from
the authors regarding themethods of generation of the random list
and concealment of allocation and we judged this study at unclear
risk of bias. For two trials, neither the study publication nor the
authors provided themethod of generation of the random list; one
trial reported that allocation was concealed using sealed envelopes
prepared on a different site to recruitment of participants (Banu
2007), and the other trial reported that allocation was concealed
by sealed opaque envelopes, but this method was not used for all
participants in the trial; we judged this trial to be at high risk of
bias for allocation concealment (Placencia 1993). This inadequate
allocation concealment may have resulted in selection bias in this
trial, so we performed sensitivity analyses for all outcomes exclud-
ing participants from this trial (see Sensitivity analysis and Effects
of interventions).
(2) Trials for which no IPD were available
Two trials reported adequate methods of randomisation: random
number tables (Cereghino 1974); and simple randomisation of
block size three (Chen 1996), but they provided no details on
concealment of allocation.
Three trials reported that the participants were ’randomised’ or
’randomly allocated’, etc. but did not provide information about
the method of generation of the random list or allocation conceal-
ment (Bidabadi 2009; Cossu 1984; Czapinski 1997).
One trial reported that it concealed allocation by the use of sealed
opaque envelopes but did not report the method of generation of
the random list (Feksi 1991), and one trial reported that it “ran-
domised [children] using a scheme that balanced drug distribu-
tion by age and sex” but did not provide further details about the
method of generation of the random list (Mitchell 1987). This
trial also did not report any details on allocation concealment, and
the trial used some non-randomised children in some analyses (see
Other potential sources of bias).
Blinding
(1) Trials for which we received IPD
One trial double-blinded participants and personnel using an ad-
ditional blank tablet (Mattson 1985); however, it was unclear if
this trial blinded the outcome assessor. One trial blinded partici-
pants and the outcome assessors who performed cognitive testing
but did not blind a research assistant recruiting participants and
providing counselling on medication adherence (Ogunrin 2005).
Similarly, another trial blinded participants and a psychologist
and therapist throughout the trial, while not blinding the treat-
ing physician for practical and ethical reasons (Banu 2007). We
judged that the open-label elements of these two studies were un-
likely to have influenced the results of these trials. However, the
latter trial blinded a researcher throughout the trial duration, but
unblinded the researcher for analysis, which may have impacted
upon results. One trial, Placencia 1993, did not report any infor-
mation on blinding in the study publication, and no information
was available from the study authors. Two trials were unblinded
for “practical and ethical reasons” (de Silva 1996; Heller 1995);
however, it is likely that the unblinded design of de Silva 1996
contributed to the early withdrawal of the phenobarbitone arm,
which is likely to have had an effect on the overall results of the
trial. Further, as the two trials were conducted under the same
protocol, the open design may have also contributed to the with-
drawal rates in Heller 1995 and influenced the overall results; we
judged both trials at high risk of performance and detection bias.
(2) Trials for which no IPD were available
One trial was described as double-blind (Cossu 1984), but it was
unclear exactly whowas blinded (participants, personnel, outcome
assessors). One paediatric trial blinded participants (and parents)
and psychometric testers but unblinded clinicians for follow-up
(Mitchell 1987). One trial described that cognitive testers were
single-blinded, Chen 1996, but gave no further details on blinding
of participants and personnel.
The remaining four trials did not provide any information on
masking of participants, personnel, or outcome assessors; we
judged them tobe at unclear risk of performance anddetectionbias
(Bidabadi 2009; Cereghino 1974; Czapinski 1997; Feksi 1991).
Incomplete outcome data
(1) Trials for which we received IPD
16Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
In theory, a review using IPD should overcome issues of attrition
bias as unpublished data can be provided, unpublished outcomes
calculated, and all randomised participants can be analysed by
an intention-to-treat approach. All six trials provided IPD for all
randomised individuals and reported the extent of follow-up for
each individual; we judged all six trials to be at low risk of attrition
bias (Banu 2007; de Silva 1996; Heller 1995; Mattson 1985;
Ogunrin 2005; Placencia 1993). We queried any missing data
with the original study authors. From the information provided
by the study authors, we deemed the small amount of missing
data present (included studies) to be missing at random and not
affecting our analysis.
(2) Trials for which no IPD were available
Two trials reported attrition rates and analysed all randomised
participants using an intention-to-treat approach (Cossu 1984;
Mitchell 1987). Two trials reported attrition rates, but it was un-
clear if they analysed all participants (Cereghino 1974; Czapinski
1997), and one trial did not report attrition rates, and it was un-
clear if it analysed all participants (Bidabadi 2009). Two studies
included only those who completed the study in the final anal-
ysis (Chen 1996; Feksi 1991), excluding 6% and 17.5% of par-
ticipants, respectively, from the final results. This approach is not
intention-to-treat, so we deemed these two studies to be at a high
risk of attrition bias.
Selective reporting
We requested study protocols in all IPD requests; however, pro-
tocols were not available for any of the 13 included trials, so we
made a judgement of the risk of bias based on the information
included in the publications or from the IPD we received (see the
’Characteristics of included studies’ tables for more information).
(1) Trials for which we received IPD
In theory, a review using IPD should overcome issues of reporting
biases as unpublished data can be provided and unpublished out-
comes calculated. We received sufficient IPD to calculate the four
outcomes (’time to withdrawal of allocated treatment’, ’time to
six-month remission, ’time to 12-month remission’, and ’time to
first seizure’) for four of the six trials (de Silva 1996; Heller 1995;
Mattson 1985; Placencia 1993). The study duration of Ogunrin
2005 was 12 weeks, and all randomised participants completed
the study without withdrawing; therefore, we could only calculate
’time to first seizure’ for this trial. Banu 2007 did not record the
dates of all seizures after randomisation and dates of withdrawal for
allocated treatment for all participants; therefore, we could only
calculate ’time to first seizure’ for this trial.
(2) Trials for which no IPD were available
Four trials reported either cognitive outcomes, seizure outcomes,
adverse events, or a combination of these (Chen 1996; Cereghino
1974; Feksi 1991; Mitchell 1987). One trial reported cognitive
outcomes only, but no adverse events or seizure outcomes (Cossu
1984); however, as no protocols were available for the aforemen-
tioned three trials, we do not know whether either seizure out-
comes, recording of adverse events, or both, were planned a pri-
ori. Two trials were in abstract form only and did not provide
sufficient information to assess selective reporting bias (Bidabadi
2009; Czapinski 1997).
Other potential sources of bias
We detected another source of bias in six of the 13 included trials.
Following consistency checks of IPD for Placencia 1993 and Banu
2007, we found some inconsistencies between the data provided
and the results in the publications in terms of withdrawal and
seizure recurrences, respectively, which the authors could not re-
solve and we judged these trials to be at high risk of other bias.
We performed sensitivity analysis to investigate the impact of the
inconsistent data on our outcomes (see Sensitivity analysis and
Effects of interventions). Furthermore, we received IPD for a sev-
enth trial (Feksi 1991), but too many inconsistencies were present
for this data to be usable (see Included studies for further details).
One trial had a cross-over design (Cereghino 1974); such a de-
sign is unlikely to be appropriate for monotherapy treatment be-
cause of carryover effects from one treatment period into another
(participants were also treated during washout periods with their
’regular medication’), and such a design does not allow long-term
outcomes, such as the time-to-event outcomes of interest in this
review. For future updates of this review, we will exclude studies
of a cross-over design.
We included one trial with very small participant numbers (six
participants randomised to each drug) and very short-term follow-
up (three weeks), and it was unclear if this trial was adequately
powered and of sufficient duration to detect differences (Cossu
1984). For future updates of this review, we will review our inclu-
sion criteria in terms of participant numbers and trial duration.
Another trial had several potential sources of other bias (Mitchell
1987); there was evidence that the trial may have been under-
powered to detect differences between the treatments, one of the
tools for outcome assessment was not fully validated, and non-
randomised children from a related pilot study were included in
analysis for some of the outcomes.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings - Carbamazepine compared with phenobarbitone for
epilepsy (primary outcome); Summary of findings 2 Summary
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of findings - Carbamazepine compared with phenobarbitone for
epilepsy (secondary outcome)
Table 1 provides a summary of the outcomes reported in trials for
which no IPD were available. Table 2 gives details regarding the
number of individuals (with IPD) contributing to each analysis.
Summary of findings for the main comparison summarises results
for primary outcome ’time to withdrawal of allocated treatment’
and Summary of findings 2, for secondary outcomes ’time to six-
and 12-month remission’, and ’time to first seizure’. Figure 4,
Figure 5, Figure 6, Figure 7, Figure 8, Figure 9, Figure 10, and
Figure 11 show survival curve plots (cumulative incidence). We
produced all cumulative incidence plots in Stata software version
11.2 using data from all trials providing IPD combined (Stata
2009). We would have liked to stratify by trial in survival curve
plots, but we do not know of any software that allows for this;
we hope that such software may have been developed for future
updates of this review.
Figure 4. Time to withdrawal of allocated treatment
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Figure 5. Time to withdrawal of allocated treatment - stratified by epilepsy type
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Figure 6. Time to 12-month remission
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Figure 7. Time to 12-month remission - stratified by epilepsy type
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Figure 8. Time to six-month remission
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Figure 9. Time to six-month remission - stratified by epilepsy type
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Figure 10. Time to first seizure
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Figure 11. Time to first seizure - stratified by epilepsy type
All hazard ratios (HRs) presented below were calculated by generic
inverse variance fixed-effect meta-analysis, unless otherwise stated.
(1) Time to withdrawal of allocated treatment
For this outcome, a HR greater than one indicates a clinical ad-
vantage for carbamazepine.
Times to withdrawal of allocated treatment and reasons for with-
drawal were available for 676 participants from four of the six tri-
als providing IPD (97.8% of 691 participants from de Silva 1996,
Heller 1995, Mattson 1985, and Placencia 1993 (see Included
studies andTable 2) and 46.4%of the total 1455 participants from
the 13 included studies). Mattson 1985 did not record follow-up
data for one participant randomised to carbamazepine. de Silva
1996 did not record the randomised drug for six participants, and
the reason for withdrawal was not available for one participant
randomised to carbamazepine and could not be determined from
the case notes. Similarly, in Heller 1995, for one participant ran-
domised to carbamazepine and three participants randomised to
phenobarbitone and in Placencia 1993, for one participant ran-
domised to carbamazepine and two participants randomised to
phenobarbitone, the reason for withdrawal was not available and
could not be determined from the case notes. We did not include
these 15 participants with missing outcome data in the analysis of
’time to withdrawal of allocated treatment’. All participants com-
pleted the 12-week study in Ogunrin 2005 and so could not con-
tribute to the analysis of ’time to withdrawal of allocated treat-
ment’. From the IPD provided by Banu 2007, we were able to
establish reasons for treatment withdrawal for all participants, but
the date of withdrawal of allocated treatment was not available for
all participants (see Data extraction and management for further
details); therefore, we could not calculate the ’time to withdrawal
of allocated treatment’ for this study.
Among the 784 participants for which we had reasons for treat-
ment withdrawal (Banu 2007; de Silva 1996; Heller 1995;
Mattson 1985; Placencia 1993), 393 participants prematurely
withdrew from treatment (50%): 216 out of 415 participants ran-
domised to carbamazepine (52%) and 178 out of 369 participants
randomised to phenobarbitone (48%). (See Table 3 for reasons for
premature termination of the study by treatment and how we clas-
sified these withdrawals in analysis). We deemed 235 participants
(30%) to have withdrawn for reasons related to the study drug,
125 (30%) on carbamazepine and 110 (30%) on phenobarbitone,
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and we classed these withdrawals as ’events’ in analysis. We classed
the other 158 withdrawals to be not related to the study drug and
censored these participants in analysis, in addition to those who
completed the study without withdrawing.
The overall pooled HR (for 676 participants) was 1.49 (95% con-
fidence interval (CI) 1.15 to 1.94, P = 0.003, from fixed-effect
analysis), indicating a statistically significant advantage for carba-
mazepine; in other words, participants withdrew significantly ear-
lier fromphenobarbitone than carbamazepine in the four included
trials. There was moderate statistical heterogeneity between trials
(Chi² test = 7.07, df = 3, P = 0.07, I² statistic = 58%, see Analysis
1.1). When we repeated the analysis using random-effects, the
pooled HR was 1.50 (95% CI 0.95 to 2.38, P = 0.07), still indi-
cating an advantage for carbamazepine, but this advantage was no
longer statistically significant.
We performed sensitivity analysis excluding participants from
Placencia 1993 from analysis because of high risk of selection
bias due to inadequate allocation concealment (see Allocation
(selection bias) and Table 4). This sensitivity analysis resulted in
a larger advantage for carbamazepine with a pooled HR of 1.66
(95%CI1.25 to 2.20, P = 0.0005, calculatedwith fixed-effect) and
reduced heterogeneity (Chi² test = 3.24, df = 2, P = 0.20, I² statistic
= 35%) but no change to conclusions. Further, in Placencia 1993,
we also found inconsistencies (between IPD dataset and published
results) in the number of participantswhowithdrew fromallocated
treatment for certain reasons, which the trial authors could not
resolve. These inconsistencies were as follows.
• Results from the IPD dataset: 51 participants withdrew, 31
from carbamazepine and 20 from phenobarbitone: 16
participants left the area (lost to follow-up), 10 withdrew due to
adverse effects, 22 withdrew for personal reasons or no stated
reason (classed as an event), and three died (see Table 3).
• Results in the trial report: 53 participants withdrew, 31
from carbamazepine and 22 from phenobarbitone: 18
participants left the area (lost to follow-up), five withdrew
because of adverse effects, three died, and 27 withdrew for
personal reasons or no stated reason.
As the overall number of events and censored observations was
similar (results from the IPD dataset: 51 withdrew, 32 events, 19
censored; and results in the trial report: 53 withdrew, 32 events,
21 censored) and as our sensitivity analysis excluding results of
Placencia 1993 gave similar results and an unchanged conclusion,
we feel that these inconsistencies areminor and are unlikely to have
had a large impact on the overall results. In the primary analysis
of Placencia 1993, we classed those who withdrew for ’no clearly
articulated reason’ as events in the analysis; in other words, the
withdrawal was due to the study drug. However, it is also possible
that these participants may have withdrawn for reasons not related
to the study drug, and we therefore should have censored them in
the analysis. We performed a further sensitivity analysis censoring
the 19 participants who withdrew for ’no clearly articulated rea-
son’. Again, the results of the sensitivity analysis were similar to
the primary analysis, showing a slightly larger statistically signifi-
cant advantage for carbamazepine (pooled HR 1.65, 95% CI 1.26
to 2.17, P = 0.0003), and again, heterogeneity was substantially
reduced after censoring these participants (Chi² test = 3.25, df =
3, P = 0.35, I² statistic = 8%).
In Placencia 1993 (primary analysis with events and censored ob-
servations as summarised in Table 3), there was some evidence
that the proportional hazards assumption of the Cox model may
have been violated; the P value of the time-varying covariate was
0.084. In sensitivity analysis under our alternative assumption re-
garding censoring (we censored participants who withdrew for ’no
clearly articulated reason’ rather than analyse them as events), there
was no evidence that the proportional hazards assumption of the
Cox model was violated; the P value of the time-varying covariate
was 0.824. We therefore assume that the non-proportionality of
Placencia 1993 in our primary analysis was likely to be due to
our assumptions regarding censoring of participants. The propor-
tional hazards assumption of the Cox model was satisfied for all
other trials included in analysis.
For participants with generalised onset seizures (136), the pooled
HR was 1.53 (95% CI 0.81 to 2.88, P = 0.19; Summary of
findings for the main comparison), suggesting an advantage for
carbamazepine that was not statistically significant. There was no
evidence of statistical heterogeneity between trials (Chi² test =
0.49, df = 2, P = 0.78, I² statistic = 0%, see Analysis 1.2).
For participants with partial onset seizures (520), the pooled HR
was 1.49 (95% CI 1.12 to 2.00, P = 0.007; Summary of findings
for the main comparison), indicating a statistically significant ad-
vantage for carbamazepine, but a large amount of statistical het-
erogeneity was present between trials (Chi² test = 8.74, df = 3, P
= 0.03, I² statistic = 66%). When we repeated the analysis using
random-effects, the pooled HR for participants with partial onset
seizures was 1.58 (95% CI 0.82 to 3.06, P = 0.17), still indicating
an advantage for carbamazepine, but this advantage was no longer
statistically significant.
Overall, the pooled HR (adjusted for seizure type) was 1.50 (95%
CI 1.15 to 1.95, P = 0.003, from fixed-effect analysis; Analysis
1.2; Summary of findings for the main comparison), providing
evidence of a statistically significant advantage for carbamazepine.
When we repeated the analysis using random-effects (Chi² test =
9.24, df = 6, P = 0.16, I² statistic = 35%), the pooled HR was
1.53 (95% CI 1.02 to 2.28, P = 0.04). In this case, the advantage
of carbamazepine was still statistically significant. We found no
interaction between treatment and seizure type (generalised versus
partial onset) (Chi² test = 0.00, df = 1, P = 0.95, I² statistic = 0%).
The sensitivity analysis including only the 20 participants ran-
domised in de Silva 1996 before the withdrawal of the phenobar-
bitone arm gave similar results with a pooled HR (adjusted for
seizure type for 633 participants) of 1.42 (95% CI 1.08 to 1.86, P
= 0.01) and heterogeneity between trials was reduced to 0 in this
analysis (Chi² test = 5.66, df = 3, P = 0.14, I² statistic = 0%). Re-
sults within each seizure group were also similar in this sensitivity
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analysis, with a pooled HR (for 115 participants with generalised
seizures) of 1.37 (95% CI 0.69 to 2.73, P = 0.37, I² statistic =
0%) and a pooled HR of 1.43 (95% CI 1.06 to 1.92, P = 0.02,
I² statistic = 46%) for 498 participants with partial seizures (see
Table 4 for further details).
Following reclassification of the 65 participants aged 30 or older
with newonset generalised seizures inHeller 1995,Ogunrin 2005,
and Placencia 1993 (see Sensitivity analysis), results were very
similar and conclusions were unchanged (results available from
review authors).
Inadequate allocation concealment in Placencia 1993 may have
influenced withdrawal rates if participants, or personnel, or both,
were aware of which drug the participants had been assigned;
from the data we received, 19% of participants withdrew from the
carbamazepine arm, and 15% of participants withdrew from the
phenobarbitone arm while the other three studies included in the
analysis showed more participants withdrawing from the pheno-
barbitone arm than the carbamazepine arm. Furthermore, incon-
sistencies between published data and data provided to us and un-
clear definitions for reason of withdrawal (participants withdrew
for ’no clearly articulated reason’) was likely to have influenced the
results of our analysis. These factors in the Placencia 1993 trial
in addition to the continuation of the carbamazepine arm in de
Silva 1996 after the withdrawal of the phenobarbitone arm are all
factors that are likely to have contributed to the heterogeneity in
Analysis 1.1 and Analysis 1.2. These factors may have confounded
the results of our primary analyses in this review.
(2) Time to achieve 12-month remission
For this outcome, a HR greater than one indicates a clinical ad-
vantage for phenobarbitone.
Data for 683 participants from four trials were available for anal-
yses of time to 12-month remission and time to six-month re-
mission (98.8% of 691 participants from de Silva 1996, Heller
1995, Mattson 1985, and Placencia 1993 (see Included studies
and Table 2) and 46.9% of the total 1455 participants from the
13 included studies). Mattson 1985 recorded no follow-up data
for one participant randomised to carbamazepine. de Silva 1996
did not record the randomised drug for six participants, and in
Placencia 1993, seizure data after occurrence of first seizure were
not available for one participant randomised to phenobarbitone,
so we did not include this participant in the analyses. The study
duration of Ogunrin 2005 was 12 weeks, so 12-month remis-
sion was not possible among participants in this trial. Banu 2007
recorded the date of first seizure after randomisation, but all dates
of subsequent seizures were not available; therefore, we could cal-
culate ’time to first seizure’ but not ’time to six-month remission’
and ’time to 12-month remission’.
Two hundred and eighty out of 683 participants (41%) achieved
12-month remission; 163 out of 384 (45%) on carbamazepine
and 117 out of 319 (37%) on phenobarbitone. The overall pooled
HR (for 683 participants) was 0.93 (95% CI 0.72 to 1.19, P =
0.57; Summary of findings 2), suggesting no advantage for either
drug. There was no evidence of statistical heterogeneity between
trials (Chi² test = 3.54, df = 3, P = 0.32, I² statistic = 15%, see
Analysis 1.3).
We performed sensitivity analysis excluding participants from
Placencia 1993 from the analysis because of high risk of selection
bias due to inadequate allocation concealment (see Allocation
(selection bias) and Table 4). This sensitivity analysis resulted in a
pooledHR of 0.82 (95%CI 0.61 to 1.09, P = 0.17), suggesting an
advantage for carbamazepine that was not statistically significant.
Again, there was no evidence of statistical heterogeneity between
trials (Chi² test = 0.33, df = 2, P = 0.85, I² statistic = 0%). Our
conclusion did not change following the sensitivity analysis.
In Placencia 1993, there was evidence that the proportional haz-
ards assumption of the Cox model may have been violated; the P
value of the time-varying covariate was < 0.001. On closer inspec-
tion of the participants in Placencia 1993, all 60 participants who
achieved 12-month remission achieved immediate remission (i.e.
did not have any seizures at all in the first 12 months of follow-
up). The trial followed up a further 42 participants for more than
365 days (up to 548 days); however, none of these participants
achieved a 12-month period of seizure freedom during the trial, so
we censored them all at their last follow-up date (after 365 days).
This observation would explain the apparent change in treatment
effect over time in Placencia 1993, and therefore the violation
of the proportional hazards assumption. When we analysed sep-
arately those who achieved immediate 12-month remission, the
proportional hazards assumption was satisfied (P value of time-
varying covariate was 0.872). The proportional hazards assump-
tion of the Cox model was satisfied for all other trials included in
the analysis.
For participants with generalised onset seizures (158), the pooled
HRwas 0.64 (95%CI 0.41 to 1.01, P = 0.05; Summary of findings
2), suggesting a borderline statistically significant advantage for
carbamazepine. There was no evidence of statistical heterogeneity
between studies for participants with generalised seizures (Chi²
test = 0.61, df = 2, P = 0.74, I² statistic = 0%). For participants
with partial onset seizures (525), the pooled HR was 1.11 (95%
CI 0.81 to 1.51, P = 0.52; Summary of findings 2 ), suggesting an
advantage for phenobarbitone that was not statistically significant.
A considerable amount of statistical heterogeneity was present be-
tween studies for participants with partial onset seizures (Chi² test
= 9.06, df = 3, P = 0.03, I² statistic = 67%). When we repeated the
analysis with random-effects, the result for participants with gen-
eralised seizures was unchanged, and for participants with partial
onset seizures, the pooled HR was 1.24 (95% CI 0.69 to 2.22,
P = 0.47), showing a larger advantage for phenobarbitone that
was not statistically significant. Overall, the pooled HR (adjusted
for seizure type for 683 participants, fixed-effect) was 0.93 (95%
CI 0.72 to 1.20, P = 0.57), suggesting no clear overall advantage
for either drug, but a considerable amount of heterogeneity was
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present between studies (Chi² test = 13.48, df = 6, P = 0.04, I²
statistic = 55%). When we repeated the analysis with random-ef-
fects, results were similar and conclusions unchanged. We found a
statistically significant interaction between treatment and seizure
type (generalised versus partial onset) (Chi² test = 3.81, df = 1, P =
0.05, I² statistic = 73.8%, see Analysis 1.4, calculated with fixed-
effect).
Upon visual inspection of forest plots in Analysis 1.4, it was clear
that Placencia 1993 was the main source of the heterogeneity be-
tween studies in the subgroup of participants with partial onset
seizures. The other three studies showed moderate, non-signifi-
cant effect sizes while Placencia 1993 showed a large, significant
effect size in favour of phenobarbitone (HR 2.43, 95% CI 1.27
to 4.65). This effect was not shown in the subgroup of partici-
pants with generalised onset seizures in participants in Placencia
1993 (HR 0.48, 95% CI 0.19 to 1.18). Repeating our sensitivity
analysis from above, excluding Placencia 1993 from analysis due
to inadequate allocation concealment, heterogeneity reduced to 0
(I² statistic = 0%) in all analyses, and there was no longer evidence
of an interaction between treatment and seizure type. Results were
also changed for participants with generalised onset seizures (101)
(pooled HR 0.71, 95% CI 0.42 to 1.19, P = 0.19), showing an
advantage for carbamazepine that was no longer statistically sig-
nificant; for participants with partial onset seizures (394), a pooled
HR of 0.88 (95% CI 0.62 to 1.25, P = 0.47) showed a change in
direction of effect, now indicating an advantage for carbamazepine
that was not statistically significant. And overall, the pooled HR
(adjusted for seizure type for 495 participants) was 0.82 (95% CI
0.61 to 1.10, P = 0.18), suggesting an advantage for carbamazepine
that was not statistically significant.
The sensitivity analysis excluding participants randomised to car-
bamazepine following withdrawal of the phenobarbitone arm in
the deSilva 1996 trial gave similar results, with an estimated pooled
HR of 0.90 (95% CI 0.69 to 1.17, P = 0.42). Results within each
seizure group were also similar, with a pooledHR of 0.59 (95%CI
0.37 to 0.95, P = 0.03) for participants with generalised seizures
(137) and a pooled HR of 1.09 (95% CI 0.79 to 1.49, P = 0.61)
for participants with partial seizures (503), resulting in no changes
in conclusions (see Table 4 for further details).
Following reclassification of the 65 participants aged 30 or older
with newonset generalised seizures inHeller 1995,Ogunrin 2005,
and Placencia 1993 (see Sensitivity analysis), results were very
similar and conclusions were unchanged (results available from
review authors).
As in the analysis of our primary outcome, Placencia 1993 seemed
to be contributing the majority of the variability between trial re-
sults. This could have been a knock-on effect of the inadequate
allocation concealment in this trial, which was likely to have influ-
enced the withdrawal rates in this study, and in turn the number
of participants remaining in the trial who could achieve 12-month
remission. Again, we conclude that the inclusion of this study may
have confounded the results of this outcome.
(3) Time to achieve six-month remission
For this outcome, a HR greater than 1 indicates a clinical advan-
tage for phenobarbitone. See ’time to 12-month remission’ for de-
tails of participants included in the analyses of time to six-month
remission.
Three hundred and eighty-seven out of 683 participants (57%)
achieved six-month remission, 213 out of 384 (59%) on carba-
mazepine and 117 out of 319 (55%) on phenobarbitone. The
overall pooled HR (for 683 participants) was 1.02 (95% CI 0.83
to 1.26, P = 0.86), suggesting no advantage for either drug. There
was no evidence of statistical heterogeneity between trials (Chi²
test = 3.63, df = 3, P = 0.30, I² statistic = 17%, see Analysis 1.5).
We performed sensitivity analysis excluding participants from
Placencia 1993 from the analysis because of high risk of selection
bias due to inadequate allocation concealment (see Allocation
(selection bias) and Table 4). This sensitivity analysis resulted in a
pooledHR of 0.88 (95%CI 0.68 to 1.14, P = 0.34), suggesting an
advantage for carbamazepine that was not statistically significant.
Again, there was no evidence of statistical heterogeneity between
trials (Chi² test = 0.14, df = 2, P = 0.93, I² statistic = 0%). Our
conclusion did not change following the sensitivity analysis.
In Mattson 1985, there was an indication that the proportional
hazards assumption may have been violated (see Data synthesis);
the P value of the time-varying covariate was 0.054, and visual
inspection of the cumulative incidence plot (Figure 12) showed
crossing of the curves at around 300 days. In other words, up to
300 days, participants on phenobarbitone seemed to be achieving
six-month remission earlier than those on carbamazepine, but this
changed after 300 days. However, participant numbers were re-
duced by 300 days (83 participants at risk out of 308 randomised),
so small changes may have been magnified at this time.
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Figure 12. Time to six-month remission - Mattson 1985
As a sensitivity analysis, we fitted a piecewise Cox regression model
to investigate any change in treatment effect over time, assuming
proportional hazards within each interval. From the visual inspec-
tion of Figure 12, we split the follow-up period of Mattson 1985
into three intervals: 0 to 182.5 days (immediate six-month remis-
sion), 182.5 to 300 days, and over 300 days (maximum follow-
up: 1616 days). We estimated separate HRs for each interval.
For ’interval 0 to 182.5 days’ (74 events from 308 at participants at
risk), theHRwas 1.06 (95%CI 0.63 to 1.77, P = 0.83), indicating
no clear advantage of either drug. For ’interval 182.5 to 300 days’
(22 events from 83 participants at risk), theHR was 0.65 (95%CI
0.37 to 1.15, P = 0.14), suggesting an advantage for carbamazepine
that was not statistically significant. For ’interval over 300 days’
(20 events from 41 participants at risk), the HR was 0.92 (95%
CI 0.64 to 1.33, P = 0.65), suggesting no clear advantage of either
drug.
These results suggest some indication of a change in treatment
effect over time, with no clear advantage between the two drugs in
the early stages of the trial for immediate remission; an advantage
for carbamazepine emerged after the initial six months, which was
no longer present by the end of the study. However, the CIs of
estimates were wide, particularly for later times in the trial due to
small numbers of events and participants and risk, so we do not
have statistically significant evidence to support the hypothesis of
a change in treatment effect over time forMattson 1985. Thus, we
conclude that the observed difference in treatment effect around
180 to 300 days compared with the rest of the study follow-up was
likely to be due to chance thatmore participants on carbamazepine
achieved six-month remission than those on phenobarbitone at
this time (16 participants on carbamazepine compared with 6
on phenobarbitone in this time interval) while the numbers of
participants achieving six-month remission weremore comparable
at other time points. The proportional hazards assumption of the
Cox model was satisfied for all other trials included in the analysis.
For participants with generalised onset seizures (158), the pooled
HR was 0.69 (95% CI 0.47 to 1.01, P = 0.06), suggesting a bor-
derline statistically significant advantage for carbamazepine. There
was no evidence of statistical heterogeneity between studies for
participants with generalised seizures (Chi² test = 1.25, df = 2, P =
0.54, I² statistic = 0%). For participants with partial onset seizures
(525), the pooledHRof 1.17 (95%CI 0.90 to 1.50, P = 0.24) sug-
gested an advantage for phenobarbitone that was not statistically
significant. A considerable amount of statistical heterogeneity was
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present between studies for participants with partial onset seizures
(Chi² test = 7.99, df = 3, P = 0.05, I² statistic = 62%). When we re-
peated the analysis with random-effects, the result for participants
with generalised seizures was unchanged, and for participants with
partial onset seizures, the pooled HR of 1.15 (95% CI 0.73 to
1.82, P = 0.54) still showed an advantage for phenobarbitone that
was not statistically significant. Overall, the pooled HR (adjusted
for seizure type for 683 participants, fixed-effect) was 0.99 (95%
CI 0.80 to 1.23, P = 0.95), suggesting no clear overall advantage
for either drug, but a considerable amount of heterogeneity was
present between studies (Chi² test = 14.24, df = 6, P = 0.03, I²
statistic = 58%). When we repeated the analysis with random-ef-
fects, results were similar and conclusions unchanged. We found a
statistically significant interaction between treatment and seizure
type (generalised versus partial onset) (Chi² test = 5.00, df = 1, P =
0.03, I² statistic = 80.0%, see Analysis 1.6, calculated with fixed-
effect).
As in Analysis 1.4, from visual inspection of forest plots in Analysis
1.6, it was clear that Placencia 1993 was the main source of the
heterogeneity between studies in the subgroup of participants with
partial onset seizures. The other three studies showed moderate,
non-significant effect sizes, while Placencia 1993 showed a large,
significant effect size in favour of phenobarbitone (HR 1.95, 95%
CI 1.25 to 3.04). Again, this effect was not shown in the subgroup
of participants with generalised onset seizures in participants in
Placencia 1993 (HR 0.52, 95% CI 0.27 to 0.98). Repeating our
sensitivity analysis from above as in the analysis of ’time to 12-
month remission’, excluding Placencia 1993 from analysis because
of inadequate allocation concealment, reduced heterogeneity to 0
(I² statistic = 0%) in all analyses, and there was no longer evidence
of an interaction between treatment and seizure type. Results were
also changed for participants with generalised onset seizures (101),
with a pooled HR of 0.81 (95% CI 0.50 to 1.32, P = 0.40) show-
ing an advantage for carbamazepine that was not statistically sig-
nificant; for participants with partial onset seizures (394), a pooled
HRof 0.91 (95%CI 0.67 to 1.24, P = 0.56) showed a change in di-
rection of effect, again indicating an advantage for carbamazepine
that was not statistically significant. And overall, the pooled HR
(adjusted for seizure type for 495 participants) was 0.88 (95% CI
0.68 to 1.14, P = 0.34), suggesting an advantage for carbamazepine
that was not statistically significant.
The sensitivity analysis excluding participants randomised to car-
bamazepine following the withdrawal of the phenobarbitone arm
in the de Silva 1996 trial gave similar results, with an estimated
pooledHRof 0.97 (95%CI 0.78 to 1.21, P = 0.79). Results within
each seizure group were also similar, with a pooled HR of 0.66
(95% CI 0.45 to 0.98, P = 0.04) for participants with generalised
seizures (137) and a pooled HR of 1.14 (95% CI 0.88 to 1.48, P
= 0.31) for participants with partial seizures (503), resulting in no
changes in conclusions (see Table 4 for further details).
Following reclassification of the 65 participants aged 30 or older
with newonset generalised seizures inHeller 1995,Ogunrin 2005,
and Placencia 1993 (see Sensitivity analysis), results were very
similar and conclusions were unchanged (results available from
review authors).
As in the analysis of our outcomes ’time to withdrawal of allo-
cated treatment’ and ’time to 12-month remission’, Placencia 1993
seemed to be contributing the majority of the variability between
trial results (see the above outcomes for discussion). Again, we
conclude that the inclusion of this study may have confounded
the results of this outcome.
4) Time to first seizure post-randomisation
For this outcome, a HR greater than one indicates a clinical ad-
vantage for carbamazepine.
We had data for 822 participants from six trials (98.3% of 836
participants fromBanu 2007, de Silva 1996,Heller 1995,Mattson
1985, Ogunrin 2005, and Placencia 1993 (see Included studies
and Table 2)). de Silva 1996 did not record the randomised drug
for six participants, and dates of seizure recurrence were not avail-
able for eight participants (4 randomised to carbamazepine and
4 to phenobarbitone) in Mattson 1985; therefore, we did not in-
clude these 14 participants in the analysis.
Four hundred and fifty-three out of 822 participants (55%) experi-
enced seizure recurrence, 264 out of 434 (61%) on carbamazepine
and 189 out of 388 (49%) on phenobarbitone. The overall pooled
HR (for 822 participants) was 0.87 (95% CI 0.72 to 1.06, P =
0.18; Summary of findings 2), suggesting an advantage for phe-
nobarbitone that was not statistically significant. There was no ev-
idence of statistical heterogeneity between trials (Chi² test = 6.26,
df = 5, P = 0.28, I² statistic = 20%, see Analysis 1.7).
We performed sensitivity analysis excluding participants from
Placencia 1993 from analysis because of high risk of selection
bias due to inadequate allocation concealment (see Allocation
(selection bias) and Table 4). This sensitivity analysis resulted in
a pooled HR of 0.87 (95% CI 0.71 to 1.08, P = 0.22), still sug-
gesting an advantage for phenobarbitone that was not statistically
significant. Again, there was no significant evidence of statistical
heterogeneity between trials (Chi² test = 6.04, df = 4, P = 0.20,
I² statistic = 34%). Our conclusion did not change following the
sensitivity analysis.
In Banu 2007, we found inconsistencies (between the IPD dataset
and published results), which the study authors could not resolve;
the publication reported that only seven participants had experi-
enced no seizures from the start of treatment (3 randomised to
phenobarbitone and 4 randomised to carbamazepine); however,
from IPD provided, 21 participants did not experience seizures
from the start of treatment (12 randomised to phenobarbitone and
9 randomised to carbamazepine). Given these inconsistencies and
the limited data available on seizure recurrence, we performed sen-
sitivity analysis excluding the participants from Banu 2007 from
Analysis 1.7. This sensitivity analysis resulted in a pooled HR of
0.82 (95% CI 0.66 to 1.01, P = 0.06), suggesting a slightly larger
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advantage to phenobarbitone, which is now borderline statistically
significant. Again, there was no evidence of statistical heterogene-
ity between trials (Chi² test = 5.11, df = 4, P = 0.28, I² statis-
tic = 22%). This sensitivity analysis showed that Banu 2007, a
trial which showed a small, non-significant advantage for carba-
mazepine, may have confounded the results of our analysis; with-
out the inclusion of this trial, our results indicated a larger, bor-
derline statistically significant advantage for phenobarbitone for
the outcome of time to first seizure.
For participants with generalised onset seizures (238), the pooled
HRwas 1.23 (95%CI 0.86 to 1.77, P = 0.27; Summary of findings
2), suggesting an advantage for carbamazepine that was not statis-
tically significant. A considerable amount of statistical heterogene-
ity was present between studies for participants with generalised
onset seizures (Chi² test = 8.65, df = 4, P = 0.07, I² statistic = 54%).
For participants with partial onset seizures (584), the pooled HR
of 0.76 (95% CI 0.60 to 0.96, P = 0.02; Summary of findings 2)
suggested a statistically significant advantage for phenobarbitone.
There was no evidence of statistical heterogeneity between studies
for participants with partial onset seizures (Chi² test = 4.55, df
= 5, P = 0.47, I² statistic = 0%). When we repeated the analysis
with random-effects, the result for participants with partial on-
set seizures was unchanged, and for participants with generalised
onset seizures, the pooled HR of 1.15 (95% CI 0.66 to 2.02,
P = 0.62) still showed an advantage for carbamazepine that was
not statistically significant. Overall, the pooled HR (adjusted for
seizure type for 822 participants, fixed-effect) was 0.87 (95% CI
0.72 to 1.06, P = 0.18), suggesting an advantage for phenobarbi-
tone that was not statistically significant. A considerable amount
of heterogeneity was present between studies (Chi² test = 17.98, df
= 10, P = 0.06, I² statistic = 44%). When we repeated the analysis
with random-effects, the results were similar and conclusions un-
changed. We found a statistically significant interaction between
treatment and seizure type (generalised versus partial onset) (Chi²
test = 4.78, df = 1, P = 0.03, I² statistic = 79.1%, see Analysis 1.8,
calculated with fixed-effect).
From visual inspection of forest plots in Analysis 1.8, it was clear
that Ogunrin 2005 was the main source of the heterogeneity be-
tween studies in the subgroup of participants with generalised on-
set seizures. The other four studies showed non-significant advan-
tages of carbamazepine, while Ogunrin 2005 showed a large, sig-
nificant effect size in favour of phenobarbitone (HR 0.21, 95%
CI 0.06 to 0.76). The subgroup of participants with partial onset
seizures in participants in Ogunrin 2005 did not show this effect
(HR1.42, 95%CI 0.26 to 7.80). Reclassification of the 65 partici-
pants aged 30 or older with newonset generalised seizures inHeller
1995, Ogunrin 2005, and Placencia 1993 (see Sensitivity analysis)
into an uncertain seizure type group (see Analysis 1.9) reduced
heterogeneity between studies for the remaining 757 participants
to 0 (I² statistic = 0%); the results among participants with partial
onset seizures were unchanged. For participants with generalised
onset seizures (173), a pooled HR of 1.39 (95% CI 0.86 to 1.77,
P = 0.13) indicated a larger advantage of carbamazepine that still
does not reach statistical significance. (We note that we could not
calculate the HR for Ogunrin 2005 as following reclassification,
only a single participant remained in the phenobarbitone group
and did not experience seizure recurrence). Among the group of
participants with ’uncertain’ seizure type (65), the pooled HR of
1.22 (95% CI 0.59 to 2.51, P = 0.59) suggested an advantage of
carbamazepine that was not statistically significant. A considerable
amount of heterogeneity was present in the analysis of reclassified
participants (Chi² test = 4.78, df = 2, P = 0.09, I² statistic = 58%),
which was perhaps unsurprising as this relatively small group was
made up of participants with ’uncertain’ and likely different seizure
types. Following reclassification, a statistically significant interac-
tion between treatment and seizure type (generalised versus partial
onset) still existed (Chi² test = 6.64, df = 2, P = 0.04, I² statistic =
69.9%, see Analysis 1.9), indicating an advantage for phenobarbi-
tone for participants with partial onset seizures and an advantage
for carbamazepine for participants with generalised onset seizures.
The sensitivity analysis excluding participants randomised to car-
bamazepine following withdrawal of the phenobarbitone arm in
the deSilva 1996 trial gave similar results, with an estimated pooled
HR of 0.87 (95% CI 0.71 to 1.06, P = 0.10). Results within each
seizure group were also similar, with a pooled HR of 1.20 (95%
CI 0.82 to 1.75) for participants with generalised seizures (217)
and a pooled HR of 0.77 (95% CI 0.61 to 0.97, P = 0.007) for
participants with partial seizures (562) (see Table 4 for further de-
tails).
In de Silva 1996, there was an indication that the proportional
hazards assumption may have been violated (see Data synthesis);
the P value of the time-varying covariate was 0.08, and visual
inspection of the cumulative incidence plot (Figure 13) showed
crossing of the curves at around 100 days. In other words, up
to 100 days, more participants on carbamazepine seemed to be
experiencing first seizure recurrence earlier than those on pheno-
barbitone, but this changed after 100 days. However, participant
numbers were reduced by 100 days (26 participants at risk out
of 64 randomised), so small changes may have been magnified at
this time. Furthermore, curves also seemed to cross at around 800
days, when even fewer participants remained at risk of first seizure
in the trial (11 participants at risk out of 64 randomised).
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Figure 13. Time to first seizure - de Silva 1996
As a sensitivity analysis, we fitted a piecewise Cox regression model
to investigate any change in treatment effect over time assuming
proportional hazards within each interval. From the visual inspec-
tion of Figure 13, we split the follow-up period of de Silva 1996
into three intervals: 0 to 100 days, 100 to 800 days, and over
800 days (maximum follow-up 4163 days). We estimated separate
HRs for each interval.
For ’interval 0 to 100 days’ (38 events from 64 participants at risk),
the HR was 0.92 (95% CI 0.36 to 2.34, P = 0.83), indicating
no clear advantage of either drug. For ’interval 100 to 800 days’
(14 events from 26 participants at risk), the HR was 1.06 (95%
CI 0.55 to 2.01, P = 0.86), again, suggesting no clear advantage
of either drug. Over 800 days, 11 participants remained at risk;
however, neither of the two remaining participants randomised
to phenobarbitone experienced an event (shown by the flattening
of the curve at around 700 to 800 days in Figure 13); therefore,
the HR of first seizure recurrence was undefined over this time
period. Furthermore, in sensitivity analysis excluding participants
randomised to carbamazepine following withdrawal of the phe-
nobarbitone arm in the de Silva 1996 trial, there was no longer
evidence that the proportional hazards assumption had been vio-
lated; the P value of the time-varying covariate was 0.316 among
these 20 participants.
We did not find any statistically significant evidence to support
a change in treatment effect over time in de Silva 1996 for the
outcome of ’time to first seizure’. We conclude that the imbal-
ance in participant numbers in the two randomised groups (54
randomised to carbamazepine and 10 randomised to phenobar-
bitone) magnified the apparent crossing of the survival plots over
time and the majority of participants experiencing an event (60
participants experienced a seizure while only four were censored in
this analysis) was also likely to be an influence. The proportional
hazards assumption of the Cox model was satisfied for all other
trials included in the analysis.
We conclude from this analysis that there was likely to be a differ-
ence in efficacy of the drugs (in terms of time to first seizure recur-
rence after randomisation) by seizure type, that participants with
generalised seizures experience seizure recurrence later on carba-
mazepine than phenobarbitone, and that participants with partial
onset seizures experience seizure recurrence later on phenobarbi-
tone than carbamazepine. The overall trend towards an advantage
for phenobarbitone for all included participants reflects that the
majority of participants included in this analysis had partial onset
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seizures (71% of 822 included participants). It was possible that
inconsistencies in data provided to us (Banu 2007), and misclas-
sification of seizure type in participants over the age of 30 (Heller
1995; Ogunrin 2005; Placencia 1993), may have confounded the
results of this analysis. However, in a sensitivity analysis to take ac-
count of these confounding factors, the association between treat-
ment and seizure type still existed and therefore could be a true
association.
5) Adverse events
We extracted all reported information related to adverse events
from the study publications. Cossu 1984 did not report any find-
ings related to adverse events, and without access to protocols, we
are uncertain if these data were collected (see Selective reporting
(reporting bias)). (See Table 5 for details of all adverse event data
provided in the other 12 studies included in this review). Two stud-
ies reported only numbers of withdrawals due to adverse events
(Chen 1996; Czapinski 1997), and two reported the rate of adverse
events/number of participants reporting adverse events (Bidabadi
2009; Placencia 1993); these four studies did not report specific
adverse events. For the eight studies that did report specific adverse
events, the most commonly reported events (reported by two or
more studies) were:
For carbamazepine
• Gastrointestinal side-effects including abdominal pain,
nausea, and vomiting (Cereghino 1974; Mattson 1985).
• Drowsiness/tiredness/fatigue/sedation (Banu 2007; de Silva
1996; Heller 1995).
• Headaches (Banu 2007; Heller 1995).
• Motor disturbance (including ataxia, incoordination,
nystagmus, tremor, slowing of mental function, inattention,
psychomotor retardation) (Banu 2007; Mattson 1985; Ogunrin
2005).
• Dysmorphic and idiosyncratic side-effects (rash, gum
hypertrophy, hirsutism, acne, other skin problems) (Feksi 1991;
Heller 1995; Mattson 1985; Mitchell 1987; Ogunrin 2005).
• Cognitive side-effects and impairments including
depression and memory problems (Banu 2007; Feksi 1991;
Heller 1995; Ogunrin 2005).
• Behavioural-related side-effects (aggression, behavioural
changes, etc.) (Banu 2007; Feksi 1991; Mitchell 1987).
For phenobarbitone
• Gastrointestinal side-effects including abdominal pain,
nausea, and vomiting (Banu 2007; Cereghino 1974; Heller
1995; Mattson 1985).
• Drowsiness/tiredness/fatigue/sedation (Banu 2007; de Silva
1996; Heller 1995).
• Motor disturbance (including ataxia, incoordination,
nystagmus, tremor, slowing of mental function, inattention,
psychomotor retardation) (Banu 2007; Mattson 1985; Ogunrin
2005).
• Dysmorphic and idiosyncratic side-effects (rash, gum
hypertrophy, hirsutism, acne, other skin problems) (de Silva
1996; Feksi 1991; Heller 1995; Mattson 1985).
• Cognitive side-effects and impairments including
depression and memory problems (Banu 2007; Feksi 1991;
Ogunrin 2005).
• Behavioural-related side-effects (aggression, behavioural
changes, etc.) (Banu 2007; de Silva 1996; Mitchell 1987).
It was difficult to summarise the ’most common’ adverse events
overall across the 12 studies or deduce whether carbamazepine or
phenobarbitone were most associated with specific adverse events
because of the differences in methods of reporting adverse event
data across the studies (see Table 5). We did not include requests
for adverse event data for individuals in the original IPD requests
for earlier versions of this review, but we will pledge to do this in
all future IPD requests.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Carbamazepine compared with phenobarbitone for epilepsy
Patient or population: adults and children with newly onset part ial or generalised epilepsy
Settings: outpat ients
Intervention: carbamazepine
Comparison: phenobarbitone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)¹
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenobarbitone Carbamazepine
Time to achieve 12-
month remission - all
participants, stratified
by epilepsy type
Range of follow-up (all
part icipants): 0 to 4222
days
367 per 1000 346 per 1000
(280 to 422)
HR 0.93
(0.72 to 1.20)
683
(4 studies)
⊕⊕©©
low2,3
HR > 1 indicates a
clinical advantage for
phenobarbitone
Time to achieve 12-
month remission
Subgroup: generalised
onset seizures
Range of follow-up (all
part icipants): 0 to 4163
days
500 per 1000 358 per 1000
(247 to 503)
HR 0.64
(0.41 to 1.01)
158
(3 studies)
⊕⊕©©
low2,3
HR > 1 indicates a
clinical advantage for
phenobarbitone
Time to achieve 12-
month remission
Subgroup: partial on-
set seizures
Range of follow-up (all
part icipants): 0 to 4222
329 per 1000 358 per 1000
(276 to 453)
HR 1.11
(0.81 to 1.51)
525
(4 studies)
⊕⊕©©
low2,3
HR > 1 indicates a
clinical advantage for
phenobarbitone
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days
Time to first seizure -
all participants, strati-
fied by epilepsy type
Range of follow-up (all
part icipants): 0 to 4108
days
487 per 1000 536 per 1000
(467 to 604)
HR 0.87
(0.72 to 1.06)
822
(6 studies)
⊕⊕©©
low4,5,6
HR > 1 indicates a
clinical advantage for
carbamazepine
Time to first seizure -
Subgroup: generalised
onset seizures
Range of follow-up (all
part icipants): 0 to 4108
days
548 per 1000 475 per 1000
(361 to 602)
HR 1.23
(0.86 to 1.77)
238
(5 studies)
⊕⊕©©
low4,5,6
HR > 1 indicates a
clinical advantage for
carbamazepine
Time to first seizure -
Subgroup: partial on-
set seizures
Range of follow-up (all
part icipants): 0 to 4108
days
462 per 1000 557 per 1000
(475 to 644)
HR 0.76
(0.60 to 0.96)
584
(6 studies)
⊕⊕©©
low4,5,6
HR > 1 indicates a
clinical advantage for
carbamazepine
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The assumed risk is calculated as the event rate in the
phenobarbitone treatment group. The corresponding risk in the carbamazepine treatment group (and its 95% CI) is based on the assumed risk in the comparison group and
the relat ive ef fect of the intervent ion (and its 95% CI).
The corresponding risk is calculated as the assumed risk x the relat ive risk of the intervent ion where relat ive risk = (1 - exp(HR x ln(1 - assumed risk)) )/ assumed risk.
CI: conf idence interval; RR: risk rat io; HR: hazard rat io; exp: exponent ial.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Pooled HR for all part icipants adjusted for seizure type.
2There was high risk of bias for at least one element of three studies included in the analysis; de Silva 1996 and Heller 1995
were open-label, and the lack of masking may have inf luenced the withdrawal rates in the study. Placencia 1993 did not35
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adequately conceal allocat ion for all part icipants, which may have inf luenced the withdrawal rates in the study and therefore
the remission rates in the study.
3Substant ial heterogeneity was present between studies; sensit ivity analyses showed that Placencia 1993 contributed the
largest amount of variability to the analysis.
4There was high risk of bias for at least one element of four studies included in the analysis; de Silva 1996 and Heller 1995
were open-label, and the lack of masking may have inf luenced the withdrawal rates in the study. Placencia 1993 was not
adequately concealed for all part icipants, which may have inf luenced the withdrawal rates in the study and therefore the
seizure recurrence rates in the trial. There were inconsistencies between published data and IPD, which the authors could not
resolve in Banu 2007.
5Substant ial heterogeneity was present between studies; sensit ivity analyses showed that Placencia 1993 and Ogunrin 2005
contributed the largest amount of variability to the analysis.
6Misclassif icat ion of seizure type in Ogunrin 2005 for 19 individuals may have impacted on the trial result . Sensit ivity analysis
to adjust for m isclassif icat ion reduced the amount of heterogeneity in the analysis.
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D I S C U S S I O N
Summary of main results
The results of this review provide statistically significant evidence
of an advantage for carbamazepine over phenobarbitone (phe-
nobarbitone) for our primary global effectiveness outcome ’time
to withdrawal of allocated treatment’, when accounting for par-
tial onset and generalised onset seizure types of 676 participants
(pooled hazard ratio (HR) 1.50, 95% confidence interval (CI)
1.15 to 1.95, P = 0.003). However, a substantial amount of hetero-
geneity was present between individual results of the four included
studies (de Silva 1996; Heller 1995; Mattson 1985; Placencia
1993), and when we accounted for this heterogeneity in random-
effects analysis, the advantage for carbamazepine was less convinc-
ing (pooled HR was 1.53, 95% CI 1.02 to 2.28, P = 0.04). We
found no evidence of a difference between the two seizure types
included in this review with respect to our primary outcome.
Sensitivity analyses for the primary outcome showed that poor
methodological aspects of a single trial, Placencia 1993, recruit-
ing 192 participants (13% of total eligible participants from 13
trials), contributed much variability to this analysis. This study
did not adequately conceal allocation to participants, or person-
nel, or both, which may have influenced withdrawal rates in the
study. Furthermore, there were inconsistencies between reasons
for withdrawal of allocated treatment in the participant data pro-
vided to us and those reported in the published paper, in addi-
tion to unclear reasons for withdrawal, which are likely to have
introduced variability into the analysis. Also, the withdrawal of the
phenobarbitone arm within an included paediatric study, de Silva
1996, because of concerns of serious behavioural adverse events,
was likely to have introduced variability and bias into the results
of our primary outcome (see Quality of the evidence); therefore,
we encourage caution when interpreting the results of our primary
outcome.
For our two remission outcomes (’time to 12-month and six-
month remission’), we did not find any statistically significant dif-
ferences between carbamazepine and phenobarbitone overall or by
seizure type. Again, a substantial amount of variability was present
between studies, mostly contributed by Placencia 1993. We be-
lieve that it was likely that the inadequate allocation concealment
in this trial also influenced the remission outcomes (i.e. the with-
drawal rates in this study influenced by inadequate allocation con-
cealment in turn influence the number of participants remaining
in the trial who could achieve six- or 12-month remission).
In the analysis of our other secondary efficacy outcome ’time to
first seizure’, among 822 participants in six included studies (Banu
2007; de Silva 1996; Heller 1995; Mattson 1985; Ogunrin 2005;
Placencia 1993), we found evidence of an advantage of phenobar-
bitone that did not reach statistical significance (pooled HR 0.87,
95% CI 0.72 to 1.06, P = 0.18). For this outcome, we did find
a statistically significant difference in outcome by seizure type (P
value for Chi² test of subgroup differences); for 238 participants
with generalised onset seizures, the pooled HR of 1.23 (95% CI
0.86 to 1.77, P = 0.27) suggested an advantage for carbamazepine
that was not statistically significant, and for 584 participants with
partial onset seizures, the pooledHRof 0.76 (95%CI0.60 to 0.96,
P = 0.02) suggested a statistically significant advantage for pheno-
barbitone. Again, there was variability between individual study
results likely to be due to the methodological aspects of Placencia
1993 discussed above, inconsistencies between data provided and
published data in Banu 2007, and potential misclassification of
seizure type, particularly evident in Ogunrin 2005. However, fol-
lowing sensitivity analyses to account for these potential sources
of variability, the association between outcome and seizure type
remained statistically significant; therefore, we conclude that par-
ticipants with generalised seizures experience seizure recurrence
later on carbamazepine than phenobarbitone and that participants
with partial onset seizures experience seizure recurrence later on
phenobarbitone than carbamazepine. We also conclude that the
overall trend in favour of phenobarbitone for this outcome was
likely to reflect the distribution of seizure types of participants in-
cluded in this analysis (71% of included participants were classi-
fied as having partial onset seizures).
The direction of the association between seizure type and out-
come (advantage for carbamazepine for generalised seizures and
advantage for phenobarbitone for partial seizures) was unexpected
given documented evidence that carbamazepine may exacerbate
some generalised seizure types, such as myoclonic and absence
seizures (Liporace 1994; Shields 1983; Snead 1985), and that cur-
rent guidelines recommend carbamazepine as a first-line drug for
the treatment of partial seizures (NICE 2012).
For all outcomes in this review, we would encourage caution over
the interpretation of the results because of concerns regarding
Overall completeness and applicability of evidence (see below),
and we would not advocate basing a choice between these two
drugs on the results of this review alone.
Overall completeness and applicability of
evidence
We believe our systematic electronic searches identified all relevant
evidence for this review. We have gratefully received IPDfor 1138
individuals (78%of individuals fromall eligible trials) from the au-
thors of seven trials (Banu 2007; de Silva 1996; Feksi 1991; Heller
1995; Mattson 1985; Ogunrin 2005; Placencia 1993), which in-
cluded a comparison of phenobarbitone with carbamazepine for
the treatment of epilepsy. However, we were not able to include
the data from one trial (Feksi 1991), recruiting 302 participants
(representing 21% of the total number in the 13 eligible trials
and 27% of the total number of participants from the trials for
which we received IPD), because of many inconsistencies in the
dataset that could not be resolved and we felt were too extensive
to account for in sensitivity analysis (see Included studies).
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We could not include in any analysis 317 individuals (22%) from
the other six relevant trials (Bidabadi 2009; Cereghino 1974; Chen
1996; Cossu 1984; Czapinski 1997; Mitchell 1987), as IPD were
not available and the published reports did not report outcomes of
interest. Therefore, in total, we were able to include data for 836
participants from six trials (57% of individuals from all eligible
trials).
However, while we received data for 836 participants for our pri-
mary effectiveness analysis, we were not able to include all data in
all of our analyses; because of the short three-month duration of
the trial, we were unable to include 37 participants from Ogunrin
2005 in our remission analysis, and in this short follow-up time, no
participants withdrew from treatment; therefore, this study could
not contribute to our primary outcome of ’time to withdrawal of
allocated treatment’ either. We were also unable to include 108
participants from Banu 2007 in analyses of treatment withdrawal
and remission as we did not receive dates of treatment withdrawals
and subsequent seizures after first seizure recurrence. Therefore,
our primary outcome was, in fact, based on 676 participants (47%
of individuals from all eligible trials).
Having to exclude data from nearly half of the eligible participants
due to lack of IPD and insufficient reporting in study publications
was likely to have impacted on the applicability of the evidence;
therefore, we encourage caution in the interpretation of all results
in this review. However, it was difficult to quantify exactly how
large this impact was on the results of this review (see Potential
biases in the review process).
Four trials contributing around 80% of the participant data to this
review recruited adults only (Heller 1995;Mattson 1985;Ogunrin
2005; Placencia 1993); the other two studies contributing around
20% of data were paediatric trials (Banu 2007; de Silva 1996).
Also, the largest single trial contributing over a third of the par-
ticipant data to this review, Mattson 1985, recruited individuals
with partial onset seizures only. Therefore, only around 30% of
participants included in this review were experiencing generalised
onset seizures. Furthermore, there is evidence within this review to
suggest that up to 27% of individuals with newly onset generalised
seizures may have had their seizure type misclassified. For these
reasons, the results of this review may not be fully generalisable
to children or to individuals with generalised onset seizures, and
more evidence recruiting these types of participants is required.
Quality of the evidence
The six trials for which IPD were made available were generally
of quite good methodological quality; however, four out of the six
trials for which we received IPD were at high risk of bias for at
least one aspect (see Figure 3), which may have introduced bias
into analyses.
Three of the trials contributing 27% of the participant data to this
review described adequate methods of randomisation and alloca-
tion concealment (de Silva 1996; Heller 1995; Ogunrin 2005);
however, the other two largest single trials contributing 50% of
participant data to this review did not describe the method of
randomisation or allocation concealment used, or both, and this
information was not available from study authors (Banu 2007;
Mattson 1985).We are uncertain whether this lack of information
has impacted on the results of this review. One study contributing
23% of participant data to this review reported that an adequate
method of allocation concealment was not used for all randomised
participants, and we believe this inadequate allocation conceal-
ment may have influenced rates of withdrawal if participants, or
clinicians, or both, were aware of the allocated treatment, which
may have had a further knock-on effect on our remission outcomes
(see Effects of interventions).
Three of the trials providing IPD blinded participants and out-
come assessors (Banu 2007; Mattson 1985; Ogunrin 2005); and
the other two trials, de Silva 1996 and Heller 1995, were designed
as pragmatic open-label trials, as masking of treatment would not
be “practicable or ethical”, would “undermine compliance”, and
would “introduce bias due to a very large dropout rate” as blinding
does not conform to standard clinical practice of increasing drug
doses to therapeutic ranges (Heller 1995).
However, despite this reasoning, withdrawal rates across the dou-
ble-blind, Mattson 1985, and open-label, de Silva 1996; Heller
1995, studies included in ’time to withdrawal of allocated treat-
ment’ were very similar (see Table 3 for further details); 37% of
participants withdrew from Mattson 1985 (40% randomised to
phenobarbitone and 36% randomised to carbamazepine), 36% of
participants withdrew fromHeller 1995 (40% randomised to phe-
nobarbitone and 28% randomised to carbamazepine), and 46% of
participants withdrew from de Silva 1996 (80% from phenobar-
bitone and 40% from carbamazepine). There was no statistically
significant evidence of a difference in withdrawal rates between
the double-blind study and the two studies of an open-label design
(Chi² test, P = 0.82). It is however, debatable whether double-
blind design is the most appropriate for trials of monotherapy in
epilepsy of long duration, and whether such a design does have
an impact upon the dropout rate, and therefore, the results of the
trial. The overall withdrawal rate in de Silva 1996 was greatly in-
fluenced by the high withdrawal rate of children randomised to
phenobarbitone (80%), which led to the withdrawal of that treat-
ment arm from the four-treatment study because of concerns of
serious adverse events. It is difficult to know if preconceptions of
phenobarbitone and documented associations of the drug with ad-
verse behavioural effects in children directly led to the withdrawal
of the drug and if the same outcome would have occurred if the
study had been double-blinded. It is also interesting to note that
within the other paediatric study within this review conducted in a
rural area of Bangladesh (Banu 2007), there were no documented
withdrawals of the allocated treatment (carbamazepine or pheno-
barbitone) due to adverse events, and in fact, in this study, sig-
nificantly more children withdrew from carbamazepine than phe-
nobarbitone for reasons related to the study drug (11% withdrew
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from phenobarbitone, 26% withdrew from carbamazepine, Chi²
test, P = 0.05, see Table 3). Unfortunately, we could not include
this study in the analysis of ’time to withdrawal of allocated treat-
ment’ as dates of treatment withdrawal were not available for all
participants. Furthermore, a trial comparing phenobarbitone with
phenytoin conducted in India, Pal 1998, in which phenobarbi-
tone was concluded to be an “effective and acceptable antiepileptic
drug for rural Indian children” did not report concerns regarding
adverse events of phenobarbitone in children.
We note the influence of country of recruitment over the method-
ological design and perhaps the results of the trial; within the USA
and Europe where many treatment options are available, pheno-
barbitone is no longer considered to be a first-line agent in favour of
more tolerable first-line agents, such as carbamazepine and lamot-
rigine (NICE 2012), whereas in developing or rural regions where
income is limited and newer generation antiepileptic drugs are not
readily available or affordable, older and cheaper drugs, such as
phenobarbitone, are more likely to be used as comparators.
While an IPD approach to analysis allows us to use unpublished
data, therefore, reducing attrition and reporting bias, for two of
the studies contributing 36% of participant data, we found incon-
sistencies between published data and participant data provided
to us in terms of withdrawal information and seizure recurrence,
respectively (Banu 2007; Placencia 1993), which the study au-
thors could not resolve. In both cases, it was likely that the in-
consistencies within these studies contributed to the considerable
heterogeneity present within the analyses in this review.
Further differences between the studies were in the population
recruited (age of participants and seizure types). We discuss these
differences in Potential biases in the review process.
Trials for which no IPD were available were generally of poorer
quality than those for which we received IPD. A lot of method-
ological information in these studies was not reported or unclear:
two trials presented incomplete outcome data following exclusion
of participants (Chen 1996; Feksi 1991); one study used an in-
adequate cross-over design for investigating monotherapy treat-
ments (Cereghino 1974); two trials were likely to have been un-
derpowered to detect a difference between the drugs (Cossu 1984;
Mitchell 1987); one trial may have been underpowered, too; and
two trials available only in abstract or summary form, provided
only very limited information on trial methodology (Bidabadi
2009; Czapinski 1997).
Overall, because of the documented methodological issues that
may have introduced bias into our meta-analyses, we rated the evi-
dence provided in this review as ’low’ quality according toGRADE
criteria (See Summary of findings for the main comparison and
Summary of findings 2) and would not advocate use of the evi-
dence in this review for clinical decision-making between the two
drugs.
Potential biases in the review process
We were able to include IPD for 836 out of 1455 eligible partic-
ipants (57%) from six out of 13 studies in this review and con-
ducted all analyses as IPD analyses. Such an approach has many
advantages, such as allowing the standardisation of definitions of
outcomes across trials, and attrition and reporting biases are re-
duced as we can perform additional analyses and calculate addi-
tional outcomes fromunpublished data. For the outcomeswe used
in this review that are of a time-to-event nature, an IPD approach
is considered to be the ’gold standard’ approach to analysis (Parmar
1998).
However, despite the advantages of this approach, for reasons out
of our control, we were not able to obtain IPD for 619 participants
from seven eligible studies, and no aggregate datawere available for
our outcomes of interest in study publications; therefore, we had
to exclude 43% of eligible participants from our analyses, which
may have introduced bias into the review.
Given that no statistically significant differences were found be-
tween the drugs in terms of proportions of participants seizure-
free and proportions of participants withdrawing from allocated
treatment in the seven studies for which IPD were not available
(where recorded, see Table 1), we do not believe that our conclu-
sions would have changed for the outcomes of this review had the
IPD for the seven studies been available. We do however, recom-
mend caution when interpreting results of analyses of this review
because of potential retrieval bias from the exclusion of 43% of
eligible participants from seven studies in this review.
Furthermore, five out of the seven studies that we were not able to
include in meta-analysis were at high risk of bias for at least one
methodological aspect (see Figure 3 and Risk of bias in included
studies); therefore, inclusion of this data may have introduced bias
into our results. We also judged four out of the six studies with
IPD provided for analysis to be at high risk of bias for at least one
methodological element; we addressed these issues in sensitivity
analysis and discussed at length for each analysis (see Sensitivity
analysis and Effects of interventions).
We have good evidence from previous reviews conducted by the
Cochrane Epilepsy Group that misclassification of seizure type is
an important issue in epilepsy trials (Marson 2000; Nolan 2013b).
We believe that the results of the original trials, and hence the
results of the outcome ’time to first seizure’, are likely to have
been confounded by classification bias, particularly the 19 indi-
viduals from Ogunrin 2005 classified with new onset generalised
seizures over the age of 30, and Malafosse 1994, contributing a
large amount of variability to the analysis of ’time to first seizure’.
Ogunrin 2005 classified generalised and partial onset seizures ac-
cording to the International LeagueAgainst Epilepsy (ILAE) classi-
fication of 1981 (Commission 1981), rather than the revised ILAE
classification in 1989 (Commission 1989), which may have led to
misclassification. Furthermore, Ogunrin 2005 was conducted in
Nigeria, a developing country without access to the same facilities
as trials conducted in the USA and Europe; therefore, seizure types
were classified clinically, and electroencephalographics (EEGs)/
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magnetic resonance images (MRIs) were not required for diagno-
sis of epilepsy. Clinical classification may also have contributed to
potential misclassification in this study.
Finally, we made some assumptions in the statistical methodology
used in this review. Firstly, when we received only follow-up dates
and seizure frequencies, we used linear interpolation to estimate
seizure times. We are aware that an individual’s seizure patterns
may be non-linear; therefore, we recommend caution when inter-
preting the numerical results of the seizure-related outcomes. We
also made an assumption that treatment effect for each outcome
did not change over time (proportional hazards assumption, see
Data synthesis). For all four of the outcomes, there was evidence
that one of the trials may have violated this assumption. Sensitivity
analysis showed that changes in treatment effect tended to occur
in the later stages of the studies when small participant numbers
were being followed up; therefore, small changes in treatment ef-
fect would be magnified. However, we are aware that in studies
of long duration (de Silva 1996, Heller 1995, and Mattson 1985
followed up participants for between 3 and 10 years), the assump-
tion of treatment effect remaining constant over time is unlikely
to be appropriate, for example, there is likely to be a difference
between participants who achieve immediate remission compared
with participants who achieve later remission. Therefore, if more
data can be made available to us for updates of this review, we
would like to perform statistical analyses that allow for treatment
effects to vary over time.
Agreements and disagreements with other
studies or reviews
We have found no consistent differences in individual trials be-
tween phenobarbitone and carbamazepine with respect to seizure
control or seizure type (Banu 2007; Bidabadi 2009; Cereghino
1974; Chen 1996; Cossu 1984; Czapinski 1997; de Silva 1996;
Feksi 1991; Heller 1995; Mattson 1985; Mitchell 1987; Ogunrin
2005; Placencia 1993). However, within these trials, confidence
intervals around estimates have been wide and equivalence cannot
be inferred.
The adverse event profiles of the two drugs, particularly phenobar-
bitone with relation to behavioural changes in children, are well
documented (see Description of the intervention). Results of this
review suggest that phenobarbitone may bemore likely to be with-
drawn earlier than carbamazepine; however, results across studies
were variable and should be interpreted with caution. There was
no evidence in this review that participants are more likely to with-
draw from phenobarbitone due to adverse events compared with
carbamazepine. We found no differences between the two drugs
in terms of time to remission of seizures; however, we found evi-
dence of an advantage for phenobarbitone in terms of time to first
seizure recurrence for partial onset seizures and an advantage for
carbamazepine in terms of time to first seizure recurrence for gen-
eralised onset seizures. This result goes against documented evi-
dence that carbamazepinemay exacerbate some generalised seizure
types (Liporace 1994; Shields 1983; Snead 1985), and that carba-
mazepine should be one of the drugs of first choice for new onset
partial seizures (NICE 2012).
To our knowledge, together with previous versions of this review,
this is the only systematic review and meta-analysis that compares
phenobarbitone and carbamazepine monotherapy for partial on-
set seizures and generalised onset tonic-clonic seizures. A network
meta-analysis has been published (Tudur Smith 2007), compar-
ing all direct and indirect evidence from phenobarbitone, carba-
mazepine, and other standard and new antiepileptic drugs licensed
for monotherapy. Results of this network meta-analysis showed
a statistically significant advantage for carbamazepine compared
with phenobarbitone for ’time to withdrawal of allocated treat-
ment’ for participants with partial onset seizures and a statistically
significant advantage for phenobarbitone compared with carba-
mazepine for ’time to first seizure’ for participants with partial
onset seizures. No statistically significant differences were found
between the drugs for participants with generalised onset seizures.
The results of this review generally agree with the results of the net-
work meta-analysis. The network meta-analysis is currently being
updated to include more recently published studies, such as Banu
2007 and Ogunrin 2005; therefore, we will compare the results of
this review with the updated network meta-analysis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current UK guidelines recommend carbamazepine or lamotrigine
as first-line treatment for adults and childrenwith newonset partial
seizures and sodium valproate for adults and children with new
onset generalised seizures (NICE 2012).
The results of this review suggest that carbamazepine is likely to be
a more effective drug than phenobarbitone in terms of treatment
retention (withdrawals due to lack of efficacy or adverse events or
both). The results of this review also suggest an association between
treatment and seizure type for time to first seizure recurrence, with
an advantage for phenobarbitone for partial onset seizures and an
advantage for carbamazepine for generalised onset seizures. How-
ever, studies contributing to the analyses were of varying qual-
ity with variable results; therefore, we do not advise that results
of this review alone should form the basis of a treatment choice
for a patient with newly onset seizures. Because of documented
evidence of carbamazepine worsening certain generalised seizure
types and behavioural-related adverse events associated with phe-
nobarbitone, particularly in children, we emphasise caution and
careful clinical follow-up if these drugs are chosen for these spe-
cific subgroups of participants. We also recommend caution in the
use of these drugs in women of child-bearing potential because of
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documented teratogenic effects where the risk is estimated to be
two to three times that of the general population (Meador 2008;
Morrow 2006).
Implications for research
Few consistent differences in efficacy have been found between
these two commonly used antiepileptic drugs in individual trials.
The methodological quality of studies comparing these two drugs
has been variable, producing variable individual study results in-
troducing heterogeneity into the pooled results of this review and
therefore making the pooled results difficult to interpret. If there
are differences in efficacy and tolerability across heterogeneous
populations of individuals such as those studied here, it is likely
that these differences are small. It has been argued that future com-
parative antiepileptic drug trials should be powered to establish
equivalence (Jones 1996), and therefore be capable of detecting
what is considered to be the smallest important clinical difference.
This review highlights the need for the design of future antiepilep-
tic drug monotherapy trials that recruit individuals of all ages
with specific epilepsy syndromes powered to detect a difference
between particular antiepileptic drugs. An approach likely to re-
flect and inform clinical practice, as well as being statistically pow-
erful, would be to recruit heterogeneous populations for whom
epilepsy syndromes have been adequately defined, with testing for
interaction between treatment and epilepsy syndrome. In view of
potential problems of misclassification, syndromes will have to be
well defined, with adequate checking mechanisms to ensure that
classifications are accurate and a system to recognise uncertainty
surrounding epilepsy syndromes in individuals within trials.
Consideration is also required in the design of a trial regarding
whether to blind participants and outcome assessors to treatment
allocation. While an open-label design is a more pragmatic and
practical approach for large long-term studies, when trials involve
drugs with documented adverse event profiles, such as phenobar-
bitone, masking of treatment may be important to avoid precon-
ceptions of the drug being more likely to be associated with serious
adverse events, which the results of this review did not show.
The choice of outcomes at the design stage of a trial and the pre-
sentation of the results of outcomes, particularly of a time-to-event
nature, require very careful consideration. While the majority of
studies of a monotherapy design record an outcome measuring
efficacy (seizure control) and an outcome measuring tolerability
(adverse events), there is little uniformity between the definition of
the outcomes and the reporting of the summary statistics related to
the outcomes (Nolan 2013a), making an aggregate data approach
to meta-analysis in reviews of monotherapy studies impossible.
Where trial authors cannot or will not make IPD available for
analysis, we are left with no choice but to exclude a proportion
of relevant evidence from the review, which will impact upon the
interpretation of results of the review and applicability of the evi-
dence and conclusions. The International League Against Epilepsy
recommends that studies of a monotherapy design should adopt a
primary effectiveness outcome of ’time to withdrawal of allocated
treatment (retention time)’ and should be of a duration of at least
48 weeks to allow for assessment of longer-term outcomes, such as
remission (ILAE 1998; ILAE 2006). If studies followed these rec-
ommendations, an aggregate data approach to meta-analysis may
be feasible, reducing the resources and time required from an IPD
approach.
A network meta-analysis has also been published (Tudur Smith
2007), comparing all direct and indirect evidence from phenobar-
bitone, carbamazepine, and other standard and new antiepilep-
tic drugs licensed for monotherapy. This review and the network
meta-analysis will be updated as more information becomes avail-
able; however, we acknowledge that as phenobarbitone is no longer
considered to be a first-line agent for newly diagnosed individuals,
in favour of newer agents, such as lamotrigine and levetiracetam, it
is unlikely that a substantial amount of new evidence will become
available for this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Banu 2007
Methods Single-centre, double-blind randomised controlled trial of participants recruited from
clinical referral to a multidisciplinary child development centre at a children’s hospital
in Dhaka, Bangladesh
2 treatment arms: CBZ and PB
Participants 108 children between the ages of 2 to 15 with 2 or more generalised tonic-clonic, partial,
or secondarily generalised seizures in the previous year
Number randomised: CBZ = 54, PB = 54
61 male children (56%)
59 with partial seizures (55%)
26 had previous AED treatment (24%)
Mean age (range): 6 (2 to 15 years)
Study duration: 12 months
Range of follow-up: 0 to 20.5 months
Interventions Monotherapy with CBZ (immediate release) or PB
Starting daily dose: CBZ = 1.5 mg/kg/day, PB = 5 mg/kg/day
Maximum daily dose: CBZ = 4 mg/kg/day, PB = 16 mg/kg/day
Outcomes • Seizure control: seizure freedom during the last quarter of the 12-month follow-up
• Time to first seizure after randomisation
• Time to treatment withdrawal due to adverse events
• Change in behaviour from baseline according to age-appropriate questionnaire
• Incidence of behavioural side-effects
Notes We received IPD for all randomised participants. We received reasons for withdrawal
of allocated treatment as well as the date of the last follow-up visit, but withdrawal of
allocated treatment did not always coincide with the date of the last follow-up visit (i.e.
several participants had the allocated treatment substituted for the other trial drug and
continued to be followed up). Dates of withdrawal of allocated treatment could not be
provided; therefore, we could not calculate ’time to withdrawal of allocated treatment’.
We received the date of first seizure after randomisation, but dates of other seizures in
the follow-up time could not be provided; therefore, we calculated ’time to first seizure’
for all participants, but we could not calculate the time to six- and 12-month remission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were ’randomly assigned to
treatment’; the method of randomisation
was not stated and not provided by the au-
thors
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Banu 2007 (Continued)
Allocation concealment (selection bias) Low risk Allocation was concealed by sealed en-
velopes prepared on a different site to the
site of recruitment of participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, a psychologist, and a thera-
pist were blinded throughout the trial. The
treating physician was unblinded for prac-
tical and ethical reasons
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk A researcher performing outcome assess-
ment was blinded throughout the trial but
unblinded for analysis. It was unclear if this
could have influenced the results
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were reported. We analysed
all randomised participants from the IPD
provided²
Selective reporting (reporting bias) Low risk We calculated 1 outcome for this review
from the IPD provided². We could not cal-
culate other outcomes for this review as
the appropriate data were not recorded/not
available. All cognitive outcomes from the
study were well reported
Other bias High risk There were inconsistencies between rates
of seizure recurrence between the data pro-
vided and the published paper, which the
authors could not resolve (see Sensitivity
analysis).
Bidabadi 2009
Methods Six-month, systematic, simple randomised trial of children referred to a child neurology
clinic (the author was from Guilan University of Medical Sciences, Iran, so it was likely
that the study was also conducted there)
2-arm trial: CBZ and PB
Participants Children aged 2 to 12 years with partial seizures with secondary generalisation
Number randomised: CBZ = 36, PB = 35
36 male children (53%)
100% partial seizures,
the per cent newly diagnosed was not stated
Age range: 2 to 12 years
Study duration: 6 months
Mean follow-up: not stated
Interventions Monotherapy with PB or CBZ. Doses started or achieved not stated
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Bidabadi 2009 (Continued)
Outcomes • Proportion seizure-free
• Response rate and rate of side-effects
• Seizure frequency and seizure duration
Notes The trial was reported in abstract form only with very limited information. Outcomes
chosen for this review were not reported; IPD were not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial was described as a ’systematic sim-
ple randomised study’; no further informa-
tion was provided
Allocation concealment (selection bias) Unclear risk No information was provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information was provided on blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was provided on blinding.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No attrition rates were reported; it was un-
clear if all participants were analysed
Selective reporting (reporting bias) Unclear risk There was no protocol available; the study
was available in abstract format only. Out-
comes for this review were not available
Other bias Low risk We detected no other bias.
Cereghino 1974
Methods Randomised, double-blind cross-over trial with 3, 21-day treatment periods and a 2-
week washout period (regular medications used)
3 treatment arms: CBZ, phenytoin, and PB
Participants Institutionalised adult participants with uncontrolled seizures on current medication
Number randomised: PB = 45, CBZ = 45
41 participants (91%) with partial epilepsy
28 (62%) male participants
Age range: 18 to 51 years
Study duration: 13weeks (3 x 21-day treatment periods plus 2 x 2-weekwashout periods)
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Cereghino 1974 (Continued)
Interventions Monotherapy with PB or CBZ
Daily dose: PB = 300 mg/day or CBZ = 1200 mg/day
Outcomes • Behaviour outcomes
• Adverse effects
• Seizure frequency
• Time to treatment withdrawal due to poor seizure control
Notes The outcomes chosen for this review were not reported due to the cross-over design of
the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation of groups from random
number tables (confirmed by author)
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided on blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided on blinding.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal rates reported, no further in-
formation provided.
Selective reporting (reporting bias) Low risk All efficacy and tolerability outcomes spec-
ified in the methods sections reported well
in the results section.Noprotocol available,
outcomes for this review not available due
to trial cross-over design
Other bias High risk Cross-over design may not be appropriate
for monotherapy designs, likely carryover
effects from one period to another so the
comparison may not be entirely monother-
apy
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Chen 1996
Methods Randomised, parallel group study conducted in Taiwan
3 treatment arms: CBZ, PB, sodium valproate
Participants Children with 2 or more previously untreated unprovoked epileptic seizures
Number randomised: PB = 25, CBZ = 26; number analysed: PB = 23, CBZ = 25 (see
notes)
Mean age (range): PB = 9.9 (7 to 15 years), CBZ = 10.8 (7 to 15 years)
CBZ versus PB: 26 (54%) participants with partial epilepsy
25 (52%) male participants
Study duration: 12 months
Range of follow-up: not stated
Interventions Monotherapy with PB or CBZ. Dose started or achieved not stated
Outcomes • Cognitive/psychometric outcomes: IQ (WISC-R scale) and developmental delay
(Bender-Gestalt test)
• Auditory event-related potentials (neurophysiological outcome)
• Incidence of allergic reactions
• Seizure control
Notes 2 children from the PB group and 1 child from the CBZ group withdrew from the
study because of allergic reactions. Published results were presented for children who
completed the study only. Outcomes chosen for this review were not reported; IPD were
not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were allocated with “simple
randomisation of block size 3.”
Allocation concealment (selection bias) Unclear risk No information was provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The cognitive assessor was ’single-blinded’,
implying that participants and personnel
were unblinded, but no further informa-
tion was provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The cognitive assessor was single-blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal rates were reported; results
were presented only for those who com-
pleted the study (CBZ versus PB: 3/51
(6%) excluded from analysis). An ITT ap-
proach was not taken
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Chen 1996 (Continued)
Selective reporting (reporting bias) Low risk All cognitive, efficacy, and tolerability out-
comes specified in the methods sections
were reportedwell in the results section.No
protocol was available. Outcomes chosen
for this review were not reported
Other bias Low risk We detected no other bias
Cossu 1984
Methods Randomised, double-blind study to assess short-term therapy of CBZ and PB on cogni-
tive and memory function conducted in Italy 3 treatment arms: CBZ, PB, and placebo
Participants Participants with newly diagnosed and untreated temporal lobe epilepsy with no seizures
in the previous month
Number randomised: CBZ = 6, PB = 6
100% partial (temporal lobe epilepsy), 100% newly diagnosed
Mean age (SD): CBZ = 26.33 (9.73) years, PB = 18.5 (2.56) years
Age range: 15 to 45 years
1 male and 5 females in each group
Study duration: 3 weeks; all participants completed in 3 weeks
Interventions Monotherapy with CBZ or PB, Dose started and achieved not stated
Outcomes • Changes in memory function from baseline after 3 weeks of treatment (verbal,
visual, (visual-verbal and visual-non-verbal), acoustic, tactile, and spatial)
Notes The trial was published in Italian; the characteristics and outcomes were translated.
Outcomes chosen for this review were not reported; IPD were not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial was described as randomised (’ran-
domizzazione’ in Italian); no further infor-
mation was available
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial is described as double-blind (’con-
dizioni di doppia cecità’ in Italian), we as-
sume this refers to participants and person-
nel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided on blinding of
outcome assessment.
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Cossu 1984 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed this short study
and contribute to analysis
Selective reporting (reporting bias) Unclear risk Cognitive and memory outcomes de-
scribed in methods section well reported
in results section. No seizure outcomes or
adverse events reported and outcomes cho-
sen for this review not reported. No proto-
col available so unclear if seizure outcomes
were planned a priori
Other bias High risk Very small participant numbers and very
short-term follow-up. Unclear if this study
was adequately powered and of sufficient
duration to detect differences
Czapinski 1997
Methods 36-month randomised comparative study
4 treatment arms: CBZ, sodium valproate, phenytoin, PB
Participants Adults with newly diagnosed epilepsy with partial complex seizures
Number randomised: PB = 30, CBZ = 30
100% partial epilepsy (partial complex seizures)
Age range: 18 to 40 years
Percentage male and range of follow-up: not mentioned
Interventions Monotherapy with PB or CBZ
Starting doses CBZ = 400 mg/day, PB = 100 mg/day. Dose achieved not stated
Outcomes • Proportion achieving 24-month remission at 3 years and exclusions after
randomisation due to adverse effects or no efficacy
Notes This was an abstract only. Outcomes chosen for this review were not reported. IPD were
pledged but not received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study was randomised, but no further
information was provided
Allocation concealment (selection bias) Unclear risk No information was provided.
52Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Czapinski 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information was provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Exclusion rates” were reported for all treat-
ment groups; no further information was
provided
Selective reporting (reporting bias) Unclear risk No protocol was available; the study was
available in abstract format only.Outcomes
for this review were not available
Other bias Low risk We detected no other bias.
de Silva 1996
Methods Randomised, parallel group, open-label paediatric study conducted in 2 centres in the
UK
4 treatment arms: CBZ, sodium valproate, phenytoin, PB
Participants Childrenwith newly diagnosed epilepsy (2 ormore untreated partial or generalised tonic-
clonic seizures in the 12 months preceding the study)
Number randomised: PB = 10, CBZ = 54 (see notes)
35 children (55%) with partial epilepsy
34 (53%) male children
Mean age (range): 9 (3 to 16) years
Range of follow-up: 3 to 88 (months)
Interventions Monotherapy with PB or CBZ
Median daily dose achieved: PB = not stated; CBZ = 400 mg/day
Outcomes • Time to first seizure recurrence after start of therapy
• Time to 12-month remission from all seizures
• Adverse effects and withdrawals due to adverse events
Notes 6 of the first 10 children assigned to PB had unacceptable adverse effects, so no further
childrenwere assigned toPB.The 10 children randomised toPBwere retained in analysis.
We received IPD for all outcomes of this review
Risk of bias
Bias Authors’ judgement Support for judgement
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de Silva 1996 (Continued)
Random sequence generation (selection
bias)
Low risk A randomisation list was generated using
permuted blocks of size 8 or 16 with strat-
ification for centre, seizure type, and pres-
ence of neurological signs
Allocation concealment (selection bias) Low risk Allocation was concealed via 4 batches of
concealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded - the authors stated that mask-
ing of treatment would not have been
“practicable or ethical” and would have
“undermine[d] compliance”. Lack ofmask-
ing could have led to early withdrawal of
the PB arm from the trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded - the authors stated masking of
treatmentwouldnot have been “practicable
or ethical” and would have “undermine[d]
compliance”. Lack of masking could have
led to early withdrawal of the PB arm from
the trial, which was likely to have influ-
enced the overall results
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were reported; we analysed
all randomised participants from the IPD
provided²
Selective reporting (reporting bias) Low risk All outcomes were reported or calculated
with the IPD provided²
Other bias Low risk We detected no other bias
Feksi 1991
Methods Randomised parallel group trial conducted among residents of the Nakuru district, a
semi-urban population of rural Kenya
2 treatment arms: CBZ and PB
Participants Participants had a history of generalised tonic-clonic seizures and at least 2 generalised
tonic-clonic seizures within the preceding year (with or without other seizure types) and
untreated in the 3 months prior to the study. 79 (26%) participants had been treated in
the past with AEDs
Number randomised: PB = 150, CBZ = 152
115 (38%) of participants had experienced partial seizures
173 (57%) male participants
Mean age (range): 21 (6 to 65 years)
Range of follow-up: participants followed up for up to 1 year
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Feksi 1991 (Continued)
Interventions Monotherapy with CBZ or PB
Starting doses: PB: 6 to 10 years of age: 30 mg/day, 11 to 15 years of age: 45 mg/day,
16+ years of age: 60 mg/day
CBZ: 6 to 10 years of age: 400 mg/day, 11 to 15 years of age: 500 mg/day, 16+ years of
age: 600 mg/day
Dose achieved not stated
Outcomes • Adverse effects
• Withdrawals from allocated treatment
• Seizure frequency (during second 6 months of study)
Notes IPD were made available but not used because of inconsistencies and problems with the
data provided (see Included studies for further details).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised with random
number list, no information provided on
method of generating random list
Allocation concealment (selection bias) Low risk Allocation concealed via sealed opaque en-
velopes (information provided by study au-
thor)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rates reported, results presented
only for participants completing 12
months follow-up (results not presented for
53 (17.5%) participants out of 302 who
withdrew from treatment), approach is not
ITT
Selective reporting (reporting bias) Low risk Noprotocol available, outcomes chosen for
this review not reported. Seizure outcomes
and adverse events well reported
Other bias High risk Inconsistencies with IPD and published
results so IPD could not be used (see
Included studies for further details).
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Heller 1995
Methods Randomised, parallel group, open-label study conducted in 2 centres in the UK
4 treatment arms: CBZ, sodium valproate, phenytoin, PB
Participants Adults with newly diagnosed epilepsy (2 or more untreated partial or generalised tonic-
clonic seizures in the 12 months preceding the study)
Number randomised: PB = 58, CBZ = 61
49 participants (41%) with partial epilepsy
55 (46%) male participants
Mean age (range): 32 (13 to 77) years
Range of follow-up: 1 to 91 months
Interventions Monotherapy with PB or CBZ. Median daily dose achieved: PB = 105 mg/day; CBZ =
600 mg/day
Outcomes • Time to first seizure recurrence after start of therapy
• Time to 12-month remission from all seizures
• Adverse effects and withdrawals due to adverse events
Notes We received IPD for all outcomes of this review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list generated using per-
muted blocks of size 8 or 16 with stratifi-
cation for centre, seizure type and presence
of neurological signs
Allocation concealment (selection bias) Low risk Allocation concealed via 4 batches of con-
cealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded, authors state masking of treat-
ment would not be “practical” and would
have “introduced bias due to a very large
dropout rate.” Lack of blinding may have
lead to more withdrawals of PB
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded, authors state masking of treat-
ment would not be “practical” and would
have “introduced bias due to a very large
dropout rate.” Lack of blinding may have
lead to more withdrawals of PB which is
likely to have influenced the overall results
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analyses from IPD provided²
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Heller 1995 (Continued)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided²
Other bias Low risk No other bias detected
Mattson 1985
Methods Multicentre, randomised, parallel group, double-blinded study over 10 centres in the
USA with separate randomisation schemes used for each seizure type
4 treatments: CBZ, phenytoin, PB, primidone
Participants Adults with previously untreated or under-treated simple or complex partial or secondary
generalised tonic-clonic seizures
Number randomised: CBZ = 155, PB = 155
100% partial epilepsy
268 (88%) male participants
Mean age (range): 41 (18 to 82) years
Range of follow-up: 1 to 177 months
Interventions Monotherapy with PB or CBZ
Median daily dose achieved: PB = 160 mg/day; CBZ = 800 mg/day
Outcomes • Participant retention/time to drug failure (length of time participant continued to
take randomised drug)
• Composite scores of seizure frequency (seizure rates and total seizure control) and
toxicity
• Incidence of side-effects
Notes We received IPD for all outcomes of this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised with stratifi-
cation for seizure type. The method of ran-
domisationwas not stated andnot provided
by the authors
Allocation concealment (selection bias) Unclear risk No information was provided in the pub-
lication or by the study authors
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was double-blind (participants
and personnel), which was achieved using
an additional blank tablet
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Mattson 1985 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was unclear if outcome assessment was
blinded; no information was provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were reported; we analysed
all randomised participants from the IPD
provided²
Selective reporting (reporting bias) Low risk All outcomes were reported or calculated
with the IPD provided²
Other bias Unclear risk We detected no other bias.
Mitchell 1987
Methods Randomised, double-blind, single-centre, parallel paediatric study conducted in Los
Angeles, USA
2 treatment arms: CBZ and PB
Participants Children with newly diagnosed epilepsy
Number randomised: PB = 18, CBZ = 15
100% partial epilepsy, 100% newly diagnosed
20 (61%) male children
Mean age (range): PB = 7.89 (2 to 12 years), CBZ = 6.07 (2 to 12 years)
Study duration: 12 months
Range of follow-up: not reported
Interventions Monotherapy with PB or CBZ. Doses started and achieved not stated
Outcomes • Change in cognitive, intelligence (IQ), behavioural, and psychometric scores
between baseline, 6 months, and 12 months
• Compliance, drug changes, and withdrawal rates
• Seizure control at 6 and 12 months (excellent/good/fair/poor)
Notes 33 participants were randomised to PB (18) and CBZ (15) in this study; 6 children were
enrolled into a six-month pilot study (PB (4) CBZ (2)) prior to the randomised study.
The 6 children were included in six-month follow-up psychometric data
Outcomes for this review were not reported; IPD were not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk 33 children were “randomised using a
scheme that balanced drug distribution by
age and sex”; no further details were pro-
vided on the randomisation scheme. 6 non-
randomised childrenwere also used in some
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Mitchell 1987 (Continued)
analyses
Allocation concealment (selection bias) Unclear risk No information was provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial blinded participants (and parents)
; clinicians were unblinded for clinical fol-
low-up
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial blinded psychometric (cognitive)
testers blinded for clinical follow-up
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were reported; results were
reported for all children who completed
each stage of follow-up
Selective reporting (reporting bias) Low risk Cognitive/behavioural outcomes, seizure
control outcomes, and adverse events were
all well reported.Noprotocol was available;
outcomes for this review were not reported
Other bias High risk There was evidence that the studymay have
been underpowered to detect differences (e.
g. 55%power tofind a5-point difference in
IQ score). The behavioural questionnaire
was not fully validated. Non-randomised
children from a pilot study were included
in the results for psychometric outcomes
and medical outcomes
Ogunrin 2005
Methods Double-blinded, parallel group, randomised study conducted in a single-centre in Nige-
ria. 3 treatment arms: carbamazepine, phenytoin, phenobarbitone
Participants Consectuive newly diagnosed participants aged 14 or over presenting at the outpatient
neurology clinic of theUniversity TeachingHopsital, BeninCity,Nigeria, with recurrent,
untreated afebrile seizures
Number randomised: PB = 18, CBZ = 19
7 participants with partial seizures (19%)
22 male participants (59%)
Mean age (range): 23.62 years (14 to 38 years)
Range of follow-up: all participants followed up for 12 weeks
Interventions Monotherapy with PB or CBZ. Median daily dose (range): PB = 120 mg (60 to 180
mg), CBZ = 600 mg (400 mg to 1200 mg)
Outcomes • Cognitive measures (reaction times, mental speed, memory, attention)
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Ogunrin 2005 (Continued)
Notes We received IPD for all randomised participants. The study duration was 12 weeks; all
participants completed the study without withdrawing; therefore, we could not calculate
the outcomes ’time to withdrawal of allocated drug’, ’time to six-month remission’, and
’time to 12-month remission’. We calculated ’time to first seizure’ from the IPD provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study randomised participants using
simple randomisation: Each participant
was asked to pick 1 from a table of num-
bers (1 to 60); the numbers corresponded
to allocation of 1 of 3 drugs (the author
provided information)
Allocation concealment (selection bias) Low risk Recruitment/ran-
domisation of participants and allocations
of treatments took place on different sites
(the author provided information)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were single-blinded. The study
did not blind the research assistant recruit-
ing participants and counselling on medi-
cation adherence
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators performing cognitive assess-
ments were single-blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants completed the
study. We analysed all randomised partici-
pants from the IPD provided²
Selective reporting (reporting bias) Low risk We calculated 1 outcome for this review
from the IPD provided². Other outcomes
for this review were not available because of
short study length. All cognitive outcomes
from the study were well reported
Other bias Low risk We detected no other bias.
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Placencia 1993
Methods Randomised parallel group study conducted in the context of existing community health
care in a rural highland area of a developing country (Ecuador)
Participants Participants with a history of at least 2 afebrile seizures and no previous AED treatment
in the 4 weeks preceding the study were eligible
Number randomised: PB = 97, CBZ = 95
133 participants (69%) with partial epilepsy
67 (35%) male participants
Mean age (range): PB = 28.6 (2 to 68 years), CBZ = 29.2 (2 to 68 years)
Study duration: 12 months
Range of follow-up: 0 to 53.4 months
Interventions Monotherapy with PB or CBZ. Minimum maintenance doses by age groups:
2 to 5 years: PB: 15 mg/day, CBZ: 150 mg/day; 6 to 10 years: PB: 30 mg/day, CBZ:
300 mg/day; 11 to 15 years: PB: 45 mg/day, CBZ: 500 mg/day; > 16 PB: 60 mg/day,
CBZ: 600 mg/day. Doses gradually increased
Doses achieved not stated
Outcomes • Proportion seizure-free at 3-, 6-, and 12-month follow-ups
• Proportion seizure-free, with more than 50% seizure reduction and no change in
seizure frequency in 6- to 12-month follow-up period
• Incidence of adverse effects
Notes We received IPD for all outcomes used in this review. Results in the published paper
were given for 139 participants who completed 6 months’ follow-up, but we received
IPD for all 192 participants randomised
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised with random
number list, no information provided on
method of generating random list
Allocation concealment (selection bias) High risk Allocation concealed used sealed opaque
envelopes but method not used for all par-
ticipants (information provided by study
author)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided.
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Placencia 1993 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analysed from IPD provided²
Selective reporting (reporting bias) Low risk All outcomes were reported or calculated
with the IPD provided²
Other bias High risk Inconsistencies between number and rea-
sons of withdrawals between the data and
the published paper which could not be
resolved by the authors (see Sensitivity
analysis).
AED: antiepileptic drug
CBZ: carbamazepine
IPD: individual participant data
IQ: intelligence quotient
ITT: intention-to-treat
PB: phenobarbitone
WISC-R scale: the Wechsler Intelligence Scale for Children
²For studies for which we received IPD (Banu 2007; de Silva 1996; Heller 1995; Mattson 1985; Ogunrin 2005; Placencia 1993),
attrition and reporting bias were reduced as we requested attrition rates and unpublished outcome data.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bird 1966 It was unclear whether this trial was randomised and whether participants received either CBZ or PB as
monotherapy
Castro-Gago 1998 The trial was not randomised, and the treatment choice was made based on types of seizures
Cereghino 1973 This was a preliminary analysis of Cereghino 1974.
Hansen 1980 The trial was not randomised; participants were already on CBZ or PB monotherapy upon entry into the study
Kuzuya 1993 The trial was not randomised; participants were already on CBZ or PB monotherapy upon entry into the study
Marjerrison 1968 CBZ or PB therapywere added to current treatment.We could notmake a comparison betweenCBZmonother-
apy and PB monotherapy
Meador 1990 We could not make a comparison between CBZ monotherapy and PBmonotherapy. This was a cross-over trial,
but some participants were receiving treatment at the start of the first period, which had to be withdrawn slowly
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(Continued)
Sabers 1995 The trial was not fully randomised: “The treatment was chosen at random unless the individual diagnoses
required a specific drug.”
Smith 1987 This reported the same trial as Mattson 1985, and Mattson 1985 gave more relevant information.
CBZ: carbamazepine
PB: phenobarbitone
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D A T A A N D A N A L Y S E S
Comparison 1. Carbamazepine versus phenobarbitone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to withdrawal of allocated
treatment
4 676 Hazard Ratio (Fixed, 95% CI) 1.49 [1.15, 1.94]
2 Time to withdrawal of allocated
treatment - stratified by
epilepsy type
4 676 Hazard Ratio (Fixed, 95% CI) 1.50 [1.15, 1.95]
2.1 Generalised onset 3 156 Hazard Ratio (Fixed, 95% CI) 1.53 [0.81, 2.88]
2.2 Partial onset 4 520 Hazard Ratio (Fixed, 95% CI) 1.49 [1.12, 2.00]
3 Time to 12-month remission 4 683 Hazard Ratio (Fixed, 95% CI) 0.93 [0.72, 1.19]
4 Time to 12-month remission -
stratified by epilepsy type
4 683 Hazard Ratio (Fixed, 95% CI) 0.93 [0.72, 1.20]
4.1 Generalised onset 3 158 Hazard Ratio (Fixed, 95% CI) 0.64 [0.41, 1.01]
4.2 Partial onset 4 525 Hazard Ratio (Fixed, 95% CI) 1.11 [0.81, 1.51]
5 Time to six-month remission 4 683 Hazard Ratio (Fixed, 95% CI) 1.02 [0.83, 1.26]
6 Time to six-month remission -
stratified by epilepsy type
4 683 Hazard Ratio (Fixed, 95% CI) 0.99 [0.80, 1.23]
6.1 Generalised onset 3 158 Hazard Ratio (Fixed, 95% CI) 0.69 [0.47, 1.01]
6.2 Partial onset 4 525 Hazard Ratio (Fixed, 95% CI) 1.17 [0.90, 1.50]
7 Time to first seizure 6 822 Hazard Ratio (Fixed, 95% CI) 0.86 [0.71, 1.04]
8 Time to first seizure - stratified
by epilepsy type
6 822 Hazard Ratio (Fixed, 95% CI) 0.87 [0.72, 1.06]
8.1 Generalised onset 5 238 Hazard Ratio (Fixed, 95% CI) 1.23 [0.86, 1.77]
8.2 Partial onset 6 584 Hazard Ratio (Fixed, 95% CI) 0.76 [0.60, 0.96]
9 Time to first seizure - sensitivity
analysis
6 822 Hazard Ratio (Fixed, 95% CI) 0.89 [0.73, 1.09]
9.1 Generalised onset 5 173 Hazard Ratio (Fixed, 95% CI) 1.39 [0.90, 2.13]
9.2 Partial onset 6 584 Hazard Ratio (Fixed, 95% CI) 0.76 [0.60, 0.96]
9.3 Uncertain seizure type 3 65 Hazard Ratio (Fixed, 95% CI) 1.22 [0.59, 2.51]
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Analysis 1.1. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 1 Time to withdrawal of
allocated treatment.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 1 Time to withdrawal of allocated treatment
Study or subgroup Phenobarbitone Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
de Silva 1996 10 53 1.21681 (0.42147) 10.1 % 3.38 [ 1.48, 7.71 ]
Heller 1995 55 60 0.37294 (0.32307) 17.2 % 1.45 [ 0.77, 2.74 ]
Mattson 1985 155 154 0.42196 (0.1749) 58.7 % 1.52 [ 1.08, 2.15 ]
Placencia 1993 95 94 -0.24933 (0.35774) 14.0 % 0.78 [ 0.39, 1.57 ]
Total (95% CI) 315 361 100.0 % 1.49 [ 1.15, 1.94 ]
Heterogeneity: Chi2 = 7.07, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 2.98 (P = 0.0029)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 2 Time to withdrawal of
allocated treatment - stratified by epilepsy type.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 2 Time to withdrawal of allocated treatment - stratified by epilepsy type
Study or subgroup Phenobarbitone Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Generalised onset
de Silva 1996 5 25 0.75246 (0.59334) 5.2 % 2.12 [ 0.66, 6.79 ]
Heller 1995 33 36 0.23165 (0.45004) 9.0 % 1.26 [ 0.52, 3.05 ]
Placencia 1993 32 25 0.43479 (0.7385) 3.3 % 1.54 [ 0.36, 6.57 ]
Subtotal (95% CI) 70 86 17.5 % 1.53 [ 0.81, 2.88 ]
Heterogeneity: Chi2 = 0.49, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
2 Partial onset
de Silva 1996 5 28 1.71668 (0.64128) 4.4 % 5.57 [ 1.58, 19.56 ]
Heller 1995 22 24 0.62263 (0.46966) 8.3 % 1.86 [ 0.74, 4.68 ]
Mattson 1985 155 154 0.42196 (0.1749) 59.6 % 1.52 [ 1.08, 2.15 ]
Placencia 1993 63 69 -0.47609 (0.42313) 10.2 % 0.62 [ 0.27, 1.42 ]
Subtotal (95% CI) 245 275 82.5 % 1.49 [ 1.12, 2.00 ]
Heterogeneity: Chi2 = 8.74, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 2.70 (P = 0.0070)
Total (95% CI) 315 361 100.0 % 1.50 [ 1.15, 1.95 ]
Heterogeneity: Chi2 = 9.24, df = 6 (P = 0.16); I2 =35%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.3. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 3 Time to 12-month
remission.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 3 Time to 12-month remission
Study or subgroup Phenobarbitone Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
de Silva 1996 10 54 -0.0213 (0.37457) 11.6 % 0.98 [ 0.47, 2.04 ]
Heller 1995 58 61 -0.19837 (0.22998) 30.9 % 0.82 [ 0.52, 1.29 ]
Mattson 1985 155 154 -0.26961 (0.22182) 33.2 % 0.76 [ 0.49, 1.18 ]
Placencia 1993 96 95 0.33111 (0.25884) 24.4 % 1.39 [ 0.84, 2.31 ]
Total (95% CI) 319 364 100.0 % 0.93 [ 0.72, 1.19 ]
Heterogeneity: Chi2 = 3.54, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 4 Time to 12-month
remission - stratified by epilepsy type.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 4 Time to 12-month remission - stratified by epilepsy type
Study or subgroup Phenobarbitone Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Generalised onset
de Silva 1996 5 25 -0.22788 (0.57192) 5.2 % 0.80 [ 0.26, 2.44 ]
Heller 1995 33 37 -0.37813 (0.29837) 19.0 % 0.69 [ 0.38, 1.23 ]
Placencia 1993 32 26 -0.74377 (0.46466) 7.8 % 0.48 [ 0.19, 1.18 ]
Subtotal (95% CI) 70 88 32.0 % 0.64 [ 0.41, 1.01 ]
Heterogeneity: Chi2 = 0.61, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
2 Partial onset
de Silva 1996 5 29 0.43571 (0.49665) 6.9 % 1.55 [ 0.58, 4.09 ]
Heller 1995 25 24 -0.05118 (0.38589) 11.4 % 0.95 [ 0.45, 2.02 ]
Mattson 1985 155 154 -0.26961 (0.22182) 34.4 % 0.76 [ 0.49, 1.18 ]
Placencia 1993 64 69 0.88827 (0.33092) 15.4 % 2.43 [ 1.27, 4.65 ]
Subtotal (95% CI) 249 276 68.0 % 1.11 [ 0.81, 1.51 ]
Heterogeneity: Chi2 = 9.06, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 319 364 100.0 % 0.93 [ 0.72, 1.20 ]
Heterogeneity: Chi2 = 13.48, df = 6 (P = 0.04); I2 =55%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Chi2 = 3.81, df = 1 (P = 0.05), I2 =74%
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Analysis 1.5. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 5 Time to six-month
remission.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 5 Time to six-month remission
Study or subgroup Phenobarbitone Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
de Silva 1996 10 54 -0.10513 (0.37414) 8.2 % 0.90 [ 0.43, 1.87 ]
Heller 1995 58 61 -0.18771 (0.21189) 25.5 % 0.83 [ 0.55, 1.26 ]
Mattson 1985 155 154 -0.08129 (0.18849) 32.2 % 0.92 [ 0.64, 1.33 ]
Placencia 1993 96 95 0.29574 (0.18299) 34.2 % 1.34 [ 0.94, 1.92 ]
Total (95% CI) 319 364 100.0 % 1.02 [ 0.83, 1.26 ]
Heterogeneity: Chi2 = 3.63, df = 3 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 6 Time to six-month
remission - stratified by epilepsy type.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 6 Time to six-month remission - stratified by epilepsy type
Study or subgroup Phenobarbitone Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Generalised onset
de Silva 1996 5 25 -0.23975 (0.57237) 3.5 % 0.79 [ 0.26, 2.42 ]
Heller 1995 33 37 -0.1982 (0.27075) 15.9 % 0.82 [ 0.48, 1.39 ]
Placencia 1993 32 26 -0.65802 (0.32351) 11.1 % 0.52 [ 0.27, 0.98 ]
Subtotal (95% CI) 70 88 30.5 % 0.69 [ 0.47, 1.01 ]
Heterogeneity: Chi2 = 1.25, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
2 Partial onset
de Silva 1996 5 29 0.1629 (0.49604) 4.7 % 1.18 [ 0.45, 3.11 ]
Heller 1995 25 24 -0.25213 (0.34751) 9.6 % 0.78 [ 0.39, 1.54 ]
Mattson 1985 155 154 -0.08129 (0.18849) 32.7 % 0.92 [ 0.64, 1.33 ]
Placencia 1993 64 69 0.66622 (0.2275) 22.5 % 1.95 [ 1.25, 3.04 ]
Subtotal (95% CI) 249 276 69.5 % 1.17 [ 0.90, 1.50 ]
Heterogeneity: Chi2 = 7.99, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 1.18 (P = 0.24)
Total (95% CI) 319 364 100.0 % 0.99 [ 0.80, 1.23 ]
Heterogeneity: Chi2 = 14.24, df = 6 (P = 0.03); I2 =58%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 5.00, df = 1 (P = 0.03), I2 =80%
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Analysis 1.7. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 7 Time to first seizure.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 7 Time to first seizure
Study or subgroup Phenobarbitone Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Banu 2007 54 54 0.08408 (0.24356) 16.4 % 1.09 [ 0.67, 1.75 ]
de Silva 1996 10 54 -0.27879 (0.38272) 6.6 % 0.76 [ 0.36, 1.60 ]
Heller 1995 58 61 0.03368 (0.21913) 20.3 % 1.03 [ 0.67, 1.59 ]
Mattson 1985 151 151 -0.19275 (0.1647) 35.9 % 0.82 [ 0.60, 1.14 ]
Ogunrin 2005 18 19 -1.23552 (0.52611) 3.5 % 0.29 [ 0.10, 0.82 ]
Placencia 1993 97 95 -0.25613 (0.23764) 17.2 % 0.77 [ 0.49, 1.23 ]
Total (95% CI) 388 434 100.0 % 0.86 [ 0.71, 1.04 ]
Heterogeneity: Chi2 = 6.26, df = 5 (P = 0.28); I2 =20%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 8 Time to first seizure -
stratified by epilepsy type.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 8 Time to first seizure - stratified by epilepsy type
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Generalised onset
Banu 2007 21 28 0.18623 (0.3852) 6.7 % 1.20 [ 0.57, 2.56 ]
de Silva 1996 25 5 0.6345 (0.50948) 3.9 % 1.89 [ 0.69, 5.12 ]
Heller 1995 37 33 0.26284 (0.29888) 11.2 % 1.30 [ 0.72, 2.34 ]
Ogunrin 2005 14 16 -1.57436 (0.66294) 2.3 % 0.21 [ 0.06, 0.76 ]
Placencia 1993 26 33 0.57211 (0.43926) 5.2 % 1.77 [ 0.75, 4.19 ]
Subtotal (95% CI) 123 115 29.2 % 1.23 [ 0.86, 1.77 ]
Heterogeneity: Chi2 = 8.65, df = 4 (P = 0.07); I2 =54%
Test for overall effect: Z = 1.11 (P = 0.27)
2 Partial onset
Banu 2007 33 26 0.03522 (0.3203) 9.7 % 1.04 [ 0.55, 1.94 ]
de Silva 1996 29 5 -0.98053 (0.61794) 2.6 % 0.38 [ 0.11, 1.26 ]
Heller 1995 24 25 -0.38411 (0.33802) 8.8 % 0.68 [ 0.35, 1.32 ]
Mattson 1985 151 151 -0.19275 (0.1647) 36.9 % 0.82 [ 0.60, 1.14 ]
Ogunrin 2005 5 2 0.34832 (0.87028) 1.3 % 1.42 [ 0.26, 7.80 ]
Placencia 1993 69 64 -0.62973 (0.29571) 11.4 % 0.53 [ 0.30, 0.95 ]
Subtotal (95% CI) 311 273 70.8 % 0.76 [ 0.60, 0.96 ]
Heterogeneity: Chi2 = 4.55, df = 5 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
Total (95% CI) 434 388 100.0 % 0.87 [ 0.72, 1.06 ]
Heterogeneity: Chi2 = 17.98, df = 10 (P = 0.06); I2 =44%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Chi2 = 4.78, df = 1 (P = 0.03), I2 =79%
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Analysis 1.9. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 9 Time to first seizure -
sensitivity analysis.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 9 Time to first seizure - sensitivity analysis
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Generalised onset
Banu 2007 21 28 0.18623 (0.3852) 6.8 % 1.20 [ 0.57, 2.56 ]
de Silva 1996 25 5 0.6345 (0.50948) 3.9 % 1.89 [ 0.69, 5.12 ]
Heller 1995 24 24 0.29396 (0.35583) 8.0 % 1.34 [ 0.67, 2.69 ]
Ogunrin 2005 1 10 -17.8231 (3880) 0.0 % 0.00 [ 0.0, ]
Placencia 1993 13 22 0.33847 (0.62981) 2.5 % 1.40 [ 0.41, 4.82 ]
Subtotal (95% CI) 84 89 21.2 % 1.39 [ 0.90, 2.13 ]
Heterogeneity: Chi2 = 0.51, df = 4 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
2 Partial onset
Banu 2007 33 26 0.03522 (0.3203) 9.8 % 1.04 [ 0.55, 1.94 ]
de Silva 1996 29 5 -0.98053 (0.61794) 2.6 % 0.38 [ 0.11, 1.26 ]
Heller 1995 24 25 -0.38411 (0.33802) 8.8 % 0.68 [ 0.35, 1.32 ]
Mattson 1985 151 151 -0.19275 (0.1647) 37.2 % 0.82 [ 0.60, 1.14 ]
Ogunrin 2005 5 2 0.34832 (0.87028) 1.3 % 1.42 [ 0.26, 7.80 ]
Placencia 1993 69 64 -0.62973 (0.29571) 11.5 % 0.53 [ 0.30, 0.95 ]
Subtotal (95% CI) 311 273 71.4 % 0.76 [ 0.60, 0.96 ]
Heterogeneity: Chi2 = 4.55, df = 5 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
3 Uncertain seizure type
Heller 1995 13 9 0.31135 (0.57376) 3.1 % 1.37 [ 0.44, 4.20 ]
Ogunrin 2005 13 6 -1.17569 (0.76601) 1.7 % 0.31 [ 0.07, 1.38 ]
Placencia 1993 13 11 0.96148 (0.61774) 2.6 % 2.62 [ 0.78, 8.78 ]
Subtotal (95% CI) 39 26 7.4 % 1.22 [ 0.59, 2.51 ]
Heterogeneity: Chi2 = 4.78, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 434 388 100.0 % 0.89 [ 0.73, 1.09 ]
Heterogeneity: Chi2 = 16.47, df = 13 (P = 0.22); I2 =21%
Test for overall effect: Z = 1.11 (P = 0.26)
Test for subgroup differences: Chi2 = 6.64, df = 2 (P = 0.04), I2 =70%
0.01 0.1 1 10 100
Favours PB Favours CBZ
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A D D I T I O N A L T A B L E S
Table 1. Outcomes considered and summary of results for trials with no IPD
Trial Outcomes reported Summary of results
Bidabadi 2009 1. Proportion seizure-free
2. Response rate
3. Rate of side-effects
4. Mean seizure frequency per month
5. Mean seizure duration
1. CBZ: 23/36 (64%), PB: 22/35 (63%)
2. No statistically significant difference between
groups
3. No statistically significant difference between
groups
4. CBZ: 0.66, PB: 0.8
5. CBZ: 12.63 seconds, PB: 15 seconds
Cereghino 1974 1. Behaviour measured with rating scale modified
from the Ward Behavior Rating Scale
2. Seizure control
3. Side-effects
4. Withdrawals
1. No change or improvement in behaviour was
more common on PB than CBZ (40% versus 12%);
predominant improvement with some deterioration
was more common on CBZ than PB (36% versus
12%)
2. No difference between PB and CBZ in terms of
seizure control
3. Gastrointestinal and “impaired function” side-
effects were more common on CBZ than PB in the
first few study days. Side-effects of both drugs were
minimal in later stages of the study
4. PB: 26/44 (59%), CBZ: 27/45 (60%)
Chen 1996 1. IQ scores measured with WISC-R scale
2. Time to complete the Bender-Gestalt test
3. Auditory event-related potentials
4. Incidence of allergic reactions
5. Seizure control
1. No significant difference between groups
2. No significant difference between groups
3. No significant difference between groups
4. 2 children from PB group and 1 child from CBZ
group withdrew from the study because of allergic
reactions
5. No significant difference between groups
Cossu 1984 Changes inmemory function frombaseline after 3weeks
of treatment (verbal, visual, (visual-verbal and visual-
non-verbal), acoustic, tactile, and spatial)
1. Significant decrease in visual-verbal memory for
CBZ and acoustic memory for PB
2. No significant differences for other tests
Czapinski 1997 1. Proportion achieving 24-month remission at 3
years
2. Proportion excluded after randomisation due to
adverse effects or no efficacy
1. PB: 60%, CBZ: 62%
2. PB: 33%, CBZ: 30%
Feksi 1991 1. Adverse effects
2. Withdrawals from allocated treatment
3. Seizure frequency (during second 6 months of
study, participants completing the study only)
PB (n = 123), CBZ (n = 126)
1. Minor adverse effects reported in PB: 58
participants (39%) reported 86 adverse events, CBZ:
46 participants (30%) reported 68 adverse events
2. PB: all withdrawals: PB: 27 (18%), CBZ: 26
(17%); withdrawals due to side-effects: PB: 8 (5%),
CBZ: 5 (3%)
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Table 1. Outcomes considered and summary of results for trials with no IPD (Continued)
3. Seizure-free: PB: 67 (54%), CBZ: 65 (52%); >
50% reduction of seizures from baseline: PB: 28 (23%)
, CBZ: 37 (29%); between 50% reduction to 50%
increase of seizures: PB: 18 (15%), CBZ: 17 (13%); >
50% increase in seizures: PB: 10 (8%), CBZ: 7 (6%)
Mitchell 1987 1. Cognitive/behavioural outcomes at 1, 2, 6, and
12 months
2. Compliance, drug changes, and withdrawal rates
3. Seizure control at 6 and 12 months (excellent/
good/fair/poor)
1. No significant differences between treatment
groups (children from pilot study included for 6 and
12 months)
2. Compliance (children from pilot study included):
trend towards better compliance in CBZ group (not
significant)
◦ Randomised participants only: trend
towards higher rate withdrawal from treatment in PB
group (not significant). More mild systemic side-effects
in CBZ group (significant). 3 children switched from
CBZ to PB and 1 from PB to CB following adverse
reactions
3. Seizure control at 6 months: excellent/good: PB =
15, CBZ = 13 (children from pilot study included)
fair/poor PB = 5, CBZ = 3; seizure control at 12
months: excellent/good: PB = 13, CBZ = 9 (children
from pilot study included) fair/poor PB = 4, CBZ = 4
CBZ: carbamazepine
IQ: intelligence quotient
PB: phenobarbitone
WISC-R scale: the Wechsler Intelligence Scale for Children
Table 2. Number of participants contributing to each analysis
Trial Number
randomised
Time to withdrawal
of
allocated treatment
Time to 12-month
remission
Time to six-month
remission
Time to first seizure
CBZ PB Total CBZ PB Total CBZ PB Total CBZ PB Total CBZ PB Total
Banu
2007¹
54 54 108 Information not
available
Information not
available
Information not avail-
able
54 54 108
de
Silva
1996²
54 10 64 53 10 63 54 10 64 54 10 64 54 10 64
Heller
61 58 119 60 55 115 61 58 119 61 58 119 61 58 119
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Table 2. Number of participants contributing to each analysis (Continued)
1995³
Matt-
son
1985
155 155 310 154 155 309 154 155 309 154 155 309 151 151 302
Ogun-
rin
2005
19 18 37 Information not
available
Information not
available
Information not avail-
able
19 18 37
Pla-
cen-
cia
1993
95 97 192 94 95 189 95 96 191 95 96 191 95 97 192
Total 438 392 830 361 315 676 364 319 683 364 319 683 434 388 822
CBZ: carbamazepine
PB: phenobarbitone
¹The date of withdrawal of allocated treatment was not recorded in all cases for Banu 2007, so we could not calculate ’time to withdrawal
of allocated treatment’. The date of first seizure after randomisation was recorded, but all dates of subsequent seizures were not recorded;
therefore, we could calculate ’time to first seizure’, but we could not calculate ’time to six-month remission’ and ’time to 12-month
remission’.
²We received IPD for 70 participants recruited in de Silva 1996; the randomised drug was not recorded in six participants. Reasons for
treatment withdrawal were not available for one participant randomised to CBZ; we did not include this participant in the analysis of
time to treatment withdrawal.
³Reasons for treatment withdrawal were not available for four participants (one randomised to CBZ and three to PB) in Heller 1995;
we did not include these participants in the analysis of time to treatment withdrawal.
No follow-up data after randomisation were available for one participant randomised to CBZ in Mattson 1985. Dates of seizure
recurrence were not available for seven participants (three randomised to CBZ and four to PB); we did not include these participants
in the analysis of time to first seizure.
The study duration of Ogunrin 2005 was 12 weeks; therefore, six- and 12-month remission of seizures could not be achieved, so
we could not calculate these outcomes. All randomised participants completed the study without withdrawing from treatment, so we
could not analyse the time to treatment withdrawal.
Reasons for treatment withdrawal were not available for three participants (one randomised to CBZ and two randomised to PB) in
Placencia 1993. We did not include these participants in the analysis of time to treatment withdrawal. Seizure data after occurrence of
first seizure were not available for one participant randomised to PB, so we did not include this participant in the analyses of time to
six-month and time to 12-month remission.
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Table 3. Reasons for premature discontinuation (withdrawal of allocated treatment)
Rea-
son for
early
termi-
nation
Classi-
fica-
tion
de Silva 1996¹ Heller 1995¹ Mattson 1985 Placencia 1993² Banu 2007³ Total
CBZ n
= 53
PB =
10
CBZ n
= 60
PB =
55
CBZ n
= 154
PB =
155
CBZ =
94
PB =
95
CBZ =
54
PB =
54
CBZ =
415
PB =
369
Ad-
verse
events
Event 3 2 8 12 11 5 5 5 0 0 27 24
Seizure
recur-
rence
Event 12 2 5 7 3 7 0 0 1 2 21 18
Both
seizure
recur-
rence
and
adverse
events
Event 6 4 4 3 30 26 0 0 0 0 40 33
Non-
com-
pli-
ance/
partici-
pant
choice
Event 0 0 0 0 11 19 13 9 6 0 30 28
An-
other
AED
added/
AED
changed
Event 0 0 0 0 0 3 0 0 7 4 7 7
Partici-
pant
went
into re-
mis-
sion
Cen-
sored
18 1 6 3 0 0 0 0 0 2 24 6
Lost to
follow-
up
Cen-
sored
0 0 0 0 26 26 11 5 7 15 44 46
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Table 3. Reasons for premature discontinuation (withdrawal of allocated treatment) (Continued)
Death Cen-
sored
0 0 0 0 4 2 2 1 0 0 6 3
Other Cen-
sored
0 0 0 0 16 13 0 0 0 0 16 13
Com-
pleted
the
study
(did
not
with-
draw)
Cen-
sored
14 1 37 30 53 54 63 75 33 31 200 191
AED: antiepileptic drug
CBZ: carbamazepine
n: number of individuals contributing to the outcome ’time to treatment withdrawal’
PB: phenobarbitone
¹Four participants for Heller 1995 (one on CBZ and three on PB) and one for de Silva 1996 (CBZ) had missing reasons for treatment
withdrawal.
²There were inconsistencies between IPD and the publication of Placencia 1993; we performed sensitivity analysis (see Effects of
interventions). There were missing reasons for treatment withdrawal for three participants (one on CBZ and two on PB); we did not
include these participants in the analysis.
³Banu 2007 provided reasons for treatment withdrawal, but dates of treatment withdrawal could not be provided for all participants,
so we could not calculate ’time to withdrawal of allocated treatment’.
All participants in Ogunrin 2005 completed the study without withdrawing; therefore, this study did not contribute to ’time to
withdrawal of allocated treatment’.
Death was due to reasons not related to the study drug.
Other reasons fromMattson 1985: participants developed other medical disorders including neurological and psychiatric disorders.
Table 4. Sensitivity analyses
Analysis Time to
withdrawal of
allocated
treatment
Time to 12-month
remission
Time to six-month
remission
Time to first
seizure¹
Original analysis Participants 676 (Analysis 1.2) 683 (Analysis 1.4) 683 (Analysis 1.6) 822 (Analysis 1.8)
Pooled HR (95%
CI)
P value
1.50 (1.15 to 1.95)
P = 0.003
0.93 (0.72 to 1.20)
P = 0.57
0.99 (0.80 to 1.23)
P = 0.95
0.87 (0.72 to 1.06)
P = 0.18
Heterogeneity I² statistic = 35% I² statistic = 55% I² statistic = 58% I² statistic = 44%
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Table 4. Sensitivity analyses (Continued)
Sensitivity analysis
for Placencia 1993²
Participants 487 492 492 630
Pooled HR (95%
CI)
P value
1.66 (1.25 to 2.20)
P = 0.0005
0.82 (0.61 to 1.09)
P = 0.15
0.88 (0.68 to 1.14)
P = 0.34
0.87 (0.71 to 1.08)
P = 0.22
Heterogeneity I² statistic = 35% I² statistic = 0% I² statistic = 0% I² statistic = 34%
Sensitivity analysis
for de Silva 1996³
Participants 633 640 640 779
Pooled HR (95%
CI)
P value
1.42 (1.08 to 1.86)
P = 0.01
0.90 (0.69 to 1.17)
P = 0.42
0.97 (0.78 to 1.21)
P = 0.79
0.87 (0.71 to 1.06)
P = 0.17
Heterogeneity I² statistic = 0% I² statistic = 57% I² statistic = 60% I² statistic = 39%
CI: confidence interval
HR: hazard ratio
¹We performed sensitivity analyses for potential misclassification of seizure type (see Analysis 1.9) and because of inconsistencies between
published data and IPD for Banu 2007 (see Sensitivity analysis and Effects of interventions for full details).
²We performed sensitivity analysis excluding all randomised participants in Placencia 1993 because of inadequate allocation concealment
in the study. We performed further sensitivity analysis for the outcome ’time to withdrawal of allocation concealment’ because of
inconsistencies between published data and IPD for Placencia 1993 (see Sensitivity analysis and Effects of interventions for full details).
³We performed sensitivity analysis including only the participants in de Silva 1996, which were randomised before the phenobarbitone
arm was withdrawn (see Sensitivity analysis and Effects of interventions for full details).
Table 5. Adverse event data (narrative report)
Trial Adverse event data¹ Summary of reported results
Carbamazepine (CBZ) Phenobarbitone (PB)
Banu 2007² Reported list of ’problems’ at the
last visit (provided as IPD)
CBZ (n = 54): speech/learning de-
lay (n = 6), headaches (n = 3)
, restlessness/hyperactivity/poor at-
tention/irritability (n = 6), psy-
chomotor deterioration/delay (n =
2), sleep disturbances (n = 2), fa-
tigue (n = 1), hydrocephalus (build
up of fluid on the brain) (n = 1),
CBZ hypersensitivity (n = 1), ag-
gression (n = 1), temper tantrums
(n = 1), other behavioural prob-
lems (n = 5), poor cognition (n =
1), mild stroke (n = 1), mild right-
sided weakness (n = 1), intolerable
behavioural problems (n = 6)
PB (n = 54): speech/learning delay
(n = 7), restlessness/hyperactivity/
poor attention/irritability (n = 8),
sleep disturbances (n = 1), fatigue
(n = 1), poor cognition (n = 2), ag-
gression (n = 1), temper tantrums
(n = 3), breath-holding attacks (n =
1), other behavioural problems (n
= 3), facial twitching (n = 1), left-
sided weakness (n = 1), leg pain (n
= 1), vomiting (n = 1), intolerable
behavioural problems (n = 4)
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Table 5. Adverse event data (narrative report) (Continued)
Bidabadi 2009³ Rate of drug side-effects No statistical significant difference
was seen after treatment between 2
groups in the rate of drug side-ef-
fects
No statistical significant difference
was seen after treatment between 2
groups in the rate of drug side-ef-
fects
Cereghino 1974², Most frequently observed side-ef-
fects
Gastrointestinal side-ef-
fects and “impaired function” (gen-
eral malaise). Frequency not clearly
stated
Gastrointestinal side-ef-
fects and “impaired function” (gen-
eral malaise). Frequency not clearly
stated
Chen 1996 Withdrawal from the study due to
’allergic reactions’
CBZ (n = 24): 1 participant with-
drew due to an allergic reaction
PB (n = 23): 2 participants with-
drew due to allergic reactions
Cossu 1984 No adverse events reported Not reported Not reported
Czapinski 1997³ “Exclusions due to adverse events
or no efficacy”
Proportion “excluded”: 30% (out
of 30 randomised to CBZ)
Proportion “excluded”: 33.3% (out
of 30 randomised to PB)
de Silva 1996 , “Unacceptable” adverse events
leading to drug withdrawal
CBZ (n = 54): drowsiness (n = 1),
blood dyscrasia (n = 1)
PB (n = 10): drowsiness (n = 1),
behavioural (n = 5)
Feksi 1991 Reports of minor adverse events
and side-effects leading to drug
withdrawal
CBZ (n = 150): withdrawals due to
side-effects: skin rash (n = 4), psy-
chosis (n = 1), aggressive behaviour
(n = 1)
Minor adverse events: CBZ: 46par-
ticipants reported 68 adverse events
PB (n = 152): withdrawals due to
side-effects: skin rash (n = 1), psy-
chosis (n = 1), hyperactivity (n = 3)
Minor adverse events: 58 partici-
pants reported 86 adverse events
Heller 1995 “Unacceptable” adverse events
leading to drug withdrawal
CBZ (n = 61): drowsiness (n = 3)
, rash (n = 2), headache (n = 1),
depression (n = 1)
PB (n = 58): drowsiness (n = 4),
lethargy (n = 4), rash (n = 1), dizzi-
ness (n = 2), headaches (n = 1), nau-
sea and vomiting (n = 1)
Mattson 1985² Narrative report of ’adverse effects’
and ’serious side-effects’
CBZ (n = 155): motor disturbance
(ataxia, incoordination, nystagmus,
tremor - 33%), dysmorphic and id-
iosyncratic side-effects (gumhyper-
trophy, hirsutism, acne, and rash
- 14%), gastrointestinal problems
(27%), decreased libido or impo-
tence (13%).No serious side-effects
PB (n = 155): motor disturbance
(ataxia, incoordination, nystagmus,
tremor - 24%), dysmorphic and id-
iosyncratic side-effects (gumhyper-
trophy, hirsutism, acne, and rash
-11 %), gastrointestinal problems
(13%), decreased libido or impo-
tence (16%).No serious side-effects
Mitchell 1987 Systemic side-effects and side-ef-
fects leading to drug change
CBZ (n = 15): 4 participants
switched fromCBZ to PB; 3 due to
systemic side-effects (1 with persis-
tent rashes and 1withmarked gran-
ulocytopenia (decrease of granulo-
cytes (white blood cells)) and 1 due
PB (n = 18): 1 participant switched
from PB to CBZ due to substantial
behavioural side-effects
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Table 5. Adverse event data (narrative report) (Continued)
to behavioural changes
Ogunrin 2005² Participant-reported symptomatic
complaints (provided as IPD)
CBZ (n=19),memory impairment
(n = 9), psychomotor retardation (n
= 1), inattention (n = 1), transient
rash (n = 1), CBZ-induced cough
(n = 1)
PB (n = 18), memory impairment
(n = 13), psychomotor retardation
(n = 8), inattention (n = 9)
Placencia 1993 Number of participants reporting
side-effects
CBZ (n = 95): 53 participants re-
ported at least 1 side-effect
PB (n = 97): 50 participants re-
ported at least 1 side-effect
CBZ: carbamazepine; PB: phenobarbitone
¹We recorded adverse event data as reported narratively in the publications; therefore, exact definition of a symptom may vary. Adverse
event data were supplied as IPD for Banu 2007 and Ogunrin 2005. Adverse event data were not requested in original IPD requests
(de Silva 1996; Heller 1995; Mattson 1985; Placencia 1993), but will be for all future IPD requests. For numbers of withdrawals due
to adverse events in studies for which we received IPD (Banu 2007; de Silva 1996; Heller 1995; Mattson 1985; Placencia 1993), see
Table 3.
²Bidabadi 2009 and Czapinski 1997 are abstracts only so very little information was reported.
³Participants may report more than one adverse event.
Note that the recruited participants in this study were institutionalised; therefore, the “precise nature of side-effects was not always
determinable”. The two most frequently occurring side-effects were reported as the frequency of participants reporting the side-effect
on each day of the treatment period; however, overall totals of participants reporting each side-effect were not reported.
Participants may have withdrawn due to adverse event alone or a combination of adverse events and poor efficacy (seizures).
The phenobarbitone arm of de Silva 1996 was stopped prematurely after 10 children were randomised to this arm because of concerns
over behavioural adverse events (see the ’Characteristics of included studies’ tables).
A P P E N D I C E S
Appendix 1. Cochrane Epilepsy Group Specialized Register search strategy
#1 MeSH DESCRIPTOR Carbamazepine Explode All
#2 Carbamazepine OR Carbamezepine OR CBZ OR SPD417 OR Apo-Carbamazepine OR Atretol OR Biston OR Calepsin OR
Carbagen OR Carbamazepen OR Carbatrol OR Carbazepine OR Carbelan OR Epitol OR Equetro OR Finlepsin OR Karbamazepin
OR Lexin ORNeurotol ORNovo-Carbamaz OR Nu-Carbamazepine OR Sirtal OR Stazepin OR Stazepine OR Taro-Carbamazepine
OR Tegretal OR Tegretol OR Telesmin OR Teril OR Timonil
#3 #1 OR #2
#4 MeSH DESCRIPTOR Phenobarbital Explode All
#5 Phenobarbital ORFenobarbital ORPhenobarbitolORPhenobarbitoneOR “Phenobarbituric Acid”ORPhenylethylbarbiturateOR
“Phenylethylbarbituric Acid” OR Phenylethylmalonylurea OR Adonal OR Aephenal OR Agrypnal OR Amylofene OR Aphenylbarbit
OR Aphenyletten OR Barbenyl OR Barbinal OR Barbiphen OR Barbiphenyl OR Barbipil OR Barbita OR Barbivis OR Barbonal
OR Barbophen OR Bardorm OR Bartol OR Bialminal OR Blu-Phen OR Cabronal OR Calmetten OR Calminal OR Cardenal OR
Chinoin OR Codibarbita OR Coronaletta OR Cratecil OR Damoral OR Dezibarbitur ORDormina ORDormiral OR Dormital OR
Doscalun ORDuneryl OR Ensobarb OREnsodorm OR Epanal OR EpidormOR Epilol OR Episedal OR Epsylone OR Eskabarb OR
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EtilfenOREunerylORFenbital ORFenemalORFenosedORFenylettaeORGardenalORGardepanylORGlysolettenORHaplopan
OR Haplos OR Helional OR Hennoletten OR Henotal OR Hypnaletten OR Hypnette OR Hypno-Tablinetten OR Hypnogen OR
Hypnolone OR Hypnoltol OR Hysteps OR Lefebar OR Leonal OR Lephebar OR Lepinal OR Lepinaletten OR Linasen OR Liquital
OR Lixophen OR Lubergal OR Lubrokal OR LumenOR Lumesettes OR LumesynOR Luminal OR Lumofridetten OR Luphenil OR
Luramin OR Molinal OR Neurobarb OR Nirvonal OR Noptil OR Nova-Pheno OR Nunol OR Parkotal OR Pharmetten OR Phen-
Bar OR Phenaemal OR Phenemal OR Phenemalum OR Phenobal OR Phenobarbyl OR Phenoluric OR Phenolurio OR Phenomet
OR Phenonyl OR Phenoturic OR Phenyletten OR Phenyral OR Phob OR Polcominal OR Prominal OR Promptonal OR Seda-
Tablinen OR Sedabar OR Sedicat OR Sedizorin OR Sedlyn OR Sedofen OR Sedonal OR Sedonettes OR Sevenal OR Sinoratox OR
Solfoton OR Solu-Barb OR Sombutol OR Somnolens OR Somnoletten OR Somnosan OR Somonal OR Spasepilin OR Starifen OR
Starilettae OR Stental OR Talpheno OR Teolaxin OR Teoloxin OR Thenobarbital OR Theoloxin OR Triabarb OR Tridezibarbitur
OR Triphenatol OR Versomnal OR Zadoletten OR Zadonal OR PB
#6 #4 OR #5
#7 ((adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*) not (monotherap* or alone or singl*)):TI
#8 (#3 AND #6 AND INREGISTER) NOT #7
Appendix 2. CENTRAL via CRSO search strategy
#1 MESH DESCRIPTOR Carbamazepine EXPLODE ALL TREES
#2 biston OR carbamazepin OR carbamazepina OR carbamazepine OR carbamazepinee OR carbamazepines OR carbamazepinesr OR
carbamazepinetreated OR carbatrol OR cbz OR epitol OR equetro OR neurotop OR tegretol OR teril OR timonil
#3 #1 OR #2
#4 MESH DESCRIPTOR Phenobarbital EXPLODE ALL TREES
#5 luminal OR phenobarbital OR phenobarbitalprophylaxe OR phenobarbitals OR phenobarbitol OR phenobarbitone
#6 #4 OR #5
#7 (epilep* OR seizure* OR convuls*):TI,AB,KY
#8 MESH DESCRIPTOR Epilepsy EXPLODE ALL TREES
#9 MESH DESCRIPTOR Seizures EXPLODE ALL TREES
#10 #7 OR #8 OR #9
#11 #3 AND #6 AND #10
#12 ((adjunct* OR “add-on” OR “add on” OR adjuvant* OR combination* OR polytherap*) NOT (monotherap* or alone or singl*)):
TI
#13 #11 NOT #12
#14 (“Conference Abstract”):PT AND INEMBASE
#15 #13 NOT #14
Appendix 3. MEDLINE search strategy
The following search strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials inMEDLINE
(Lefebvre 2011).
1. exp Carbamazepine/
2. (Carbam?zepine or CBZ or SPD417 or Apo-Carbamazepine or Atretol or Biston or Calepsin or Carbagen or Carbamazepen or
Carbatrol or Carbazepine or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotol or Novo-Carbamaz or
Nu-Carbamazepine or Sirtal or Stazepin or Stazepine or Taro-Carbamazepine or Tegretal or Tegretol or Telesmin or Teril or Timonil).tw.
3. 1 or 2
4. exp Phenobarbital/
5. (Fenobarbital or Phenobarbit?l or Phenobarbitone or “Phenobarbituric Acid” or Phenylethylbarbiturate or “Phenylethylbarbituric
Acid” or Phenylethylmalonylurea or Adonal or Aephenal or Agrypnal or Amylofene or Aphenylbarbit or Aphenyletten or Barbenyl or
Barbinal or Barbiphen or Barbiphenyl or Barbipil or Barbita or Barbivis or Barbonal or Barbophen or Bardorm or Bartol or Bialminal
or Blu-Phen or Cabronal or Calmetten or Calminal or Cardenal or Chinoin or Codibarbita or Coronaletta or Cratecil or Damoral or
Dezibarbitur or Dormina or Dormiral or Dormital or Doscalun or Duneryl or Ensobarb or Ensodorm or Epanal or Epidorm or Epilol
or Episedal or Epsylone or Eskabarb or Etilfen or Euneryl or Fenbital or Fenemal or Fenosed or Fenylettae or Gardenal or Gardepanyl
or Glysoletten or Haplopan or Haplos or Helional or Hennoletten or Henotal or Hypnaletten or Hypnette or Hypno-Tablinetten or
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Hypnogen or Hypnolone or Hypnoltol or Hysteps or Lefebar or Leonal or Lephebar or Lepinal or Lepinaletten or Linasen or Liquital
or Lixophen or Lubergal or Lubrokal or Lumen or Lumesettes or Lumesyn or Luminal or Lumofridetten or Luphenil or Luramin
or Molinal or Neurobarb or Nirvonal or Noptil or Nova-Pheno or Nunol or Parkotal or Pharmetten or Phen-Bar or Phenaemal or
Phenemal or Phenemalum or Phenobal or Phenobarbyl or Phenoluric or Phenolurio or Phenomet or Phenonyl or Phenoturic or
Phenyletten or Phenyral or Phob or Polcominal or Prominal or Promptonal or Seda-Tablinen or Sedabar or Sedicat or Sedizorin or
Sedlyn or Sedofen or Sedonal or Sedonettes or Sevenal or Sinoratox or Solfoton or Solu-Barb or Sombutol or Somnolens or Somnoletten
or Somnosan or Somonal or Spasepilin or Starifen or Starilettae or Stental or Talpheno or Teolaxin or Teoloxin or Thenobarbital or
Theoloxin or Triabarb or Tridezibarbitur or Triphenatol or Versomnal or Zadoletten or Zadonal or PB).tw.
6. 4 or 5
7. exp Epilepsy/
8. exp Seizures/
9. (epilep$ or seizure$ or convuls$).tw.
10. 7 or 8 or 9
11. exp Pre-Eclampsia/ or exp Eclampsia/
12. 10 not 11
13. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
14. clinical trials as topic.sh.
15. trial.ti.
16. 13 or 14 or 15
17. exp animals/ not humans.sh.
18. 16 not 17
19. 3 and 6 and 12 and 18
20. ((adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$) not (monotherap$ or alone or singl$)).ti.
21. 19 not 20
22. remove duplicates from 21
Earlier versions of this review used the following search strategy.
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. exp Randomized Controlled Trials/
4. exp Random Allocation/
5. exp Double-Blind Method/
6. exp Single-Blind Method/
7. clinical trial.pt.
8. exp Clinical Trials/
9. (clin$ adj trial$).ab,ti.
10. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ab,ti.
11. exp PLACEBOS/
12. placebo$.ab,ti.
13. random$.ab,ti.
14. exp Research Design/
15. or/1-14
16. (animals not humans).sh.
17. 15 not 16
18. phenobarbit$.tw. or exp Phenobarbital/
19. carbamazepin$.tw.
20. exp Carbamazepine/
21. 18 and (19 or 20)
22. (epilep$ or seizure$ or convulsion$).tw.
23. exp Epilepsy/
24. exp Seizures/
25. 22 or 23 or 24
26. 21 and 25
27. 26 and 17
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Appendix 4. Scopus search strategy
(((TITLE(carbamazepine OR carbamezepine OR cbz OR spd417 OR apo-carbamazepine OR atretol OR biston OR calepsin OR
carbagenORcarbamazepenORcarbatrolOR carbazepineOR carbelanOR epitolOR equetroORfinlepsinORkarbamazepinOR lexin
OR neurotol OR novo-carbamaz OR nu-carbamazepine OR sirtal OR stazepin OR stazepine OR taro-carbamazepine OR tegretal OR
tegretol OR telesmin OR teril OR timonil)) OR (ABS(carbamazepine OR carbamezepine OR cbz OR spd417 OR apo-carbamazepine
OR atretol OR biston OR calepsin OR carbagen OR carbamazepen OR carbatrol OR carbazepine OR carbelan OR epitol OR equetro
OR finlepsin OR karbamazepin OR lexinOR neurotol OR novo-carbamaz OR nu-carbamazepine OR sirtal OR stazepin OR stazepine
OR taro-carbamazepine OR tegretal OR tegretol OR telesmin OR teril OR timonil))) AND ((TITLE(phenobarbital OR fenobarbital
OR phenobarbitol OR phenobarbitone OR “Phenobarbituric Acid” OR phenylethylbarbiturate OR “Phenylethylbarbituric Acid” OR
phenylethylmalonylurea OR adonal OR aephenal OR agrypnal OR amylofene OR aphenylbarbit OR aphenyletten OR barbenyl OR
barbinal OR barbiphen OR barbiphenyl OR barbipil OR barbita OR barbivis OR barbonal OR barbophen OR bardorm OR bartol
OR bialminal OR blu-phen OR cabronal OR calmetten OR calminal OR cardenal OR chinoin OR codibarbita OR coronaletta
OR cratecil OR damoral OR dezibarbitur OR dormina OR dormiral OR dormital OR doscalun OR duneryl OR ensobarb OR
ensodorm OR epanal OR epidorm OR epilol OR episedal OR epsylone OR eskabarb OR etilfen OR euneryl OR fenbital OR fenemal
OR fenosed OR fenylettae OR gardenal OR gardepanyl OR glysoletten OR haplopan OR haplos OR helional OR hennoletten OR
henotal OR hypnaletten OR hypnette OR hypno-tablinetten OR hypnogen OR hypnolone OR hypnoltol OR hysteps OR lefebar
OR leonal OR lephebar OR lepinal OR lepinaletten OR linasen OR liquital OR lixophen OR lubergal OR lubrokal OR lumen
OR lumesettes OR lumesyn OR luminal OR lumofridetten OR luphenil OR luramin OR molinal OR neurobarb OR nirvonal
OR noptil OR nova-pheno OR nunol OR parkotal OR pharmetten OR phen-bar OR phenaemal OR phenemal OR phenemalum
OR phenobal OR phenobarbyl OR phenoluric OR phenolurio OR phenomet OR phenonyl OR phenoturic OR phenyletten OR
phenyral OR phob OR polcominal OR prominal OR promptonal OR seda-tablinen OR sedabar OR sedicat OR sedizorin OR sedlyn
OR sedofen OR sedonal OR sedonettes OR sevenal OR sinoratox OR solfoton OR solu-barb OR sombutol OR somnolens OR
somnoletten OR somnosan OR somonal OR spasepilin OR starifen OR starilettae OR stental OR talpheno OR teolaxin OR teoloxin
OR thenobarbitalOR theoloxinOR triabarbOR tridezibarbiturOR triphenatolORversomnalOR zadolettenORzadonalORpb))OR
(ABS(phenobarbital OR fenobarbital OR phenobarbitol OR phenobarbitone OR “Phenobarbituric Acid” OR phenylethylbarbiturate
OR “Phenylethylbarbituric Acid”ORphenylethylmalonylureaOR adonal OR aephenalOR agrypnal OR amylofeneOR aphenylbarbit
OR aphenyletten OR barbenyl OR barbinal OR barbiphen OR barbiphenyl OR barbipil OR barbita OR barbivis OR barbonal OR
barbophen OR bardorm OR bartol OR bialminal OR blu-phen OR cabronal OR calmetten OR calminal OR cardenal OR chinoin
OR codibarbita OR coronaletta OR cratecil OR damoral OR dezibarbitur OR dormina OR dormiral OR dormital OR doscalun
OR duneryl OR ensobarb OR ensodorm OR epanal OR epidorm OR epilol OR episedal OR epsylone OR eskabarb OR etilfen OR
euneryl OR fenbital OR fenemal OR fenosed OR fenylettae OR gardenal OR gardepanyl OR glysoletten OR haplopan OR haplos
OR helional OR hennoletten OR henotal OR hypnaletten OR hypnette OR hypno-tablinetten OR hypnogen OR hypnolone OR
hypnoltol OR hysteps OR lefebar OR leonal OR lephebar OR lepinal OR lepinaletten OR linasen OR liquital OR lixophen OR
lubergal OR lubrokal OR lumenOR lumesettesOR lumesynOR luminal OR lumofridettenOR luphenil OR luramin ORmolinal OR
neurobarbORnirvonalORnoptil ORnova-phenoORnunolORparkotalORpharmettenORphen-barORphenaemalORphenemal
OR phenemalum OR phenobal OR phenobarbyl OR phenoluric OR phenolurio OR phenomet OR phenonyl OR phenoturic OR
phenyletten OR phenyral OR phob OR polcominal OR prominal OR promptonal OR seda-tablinen OR sedabar OR sedicat OR
sedizorin OR sedlyn OR sedofen OR sedonal OR sedonettes OR sevenal OR sinoratox OR solfoton OR solu-barb OR sombutol OR
somnolens OR somnolettenOR somnosan OR somonal OR spasepilin OR starifenOR starilettae OR stental OR talphenoOR teolaxin
OR teoloxin OR thenobarbital OR theoloxin OR triabarb OR tridezibarbitur OR triphenatol OR versomnal OR zadoletten OR
zadonal OR pb))) AND ((TITLE-ABS-KEY(epilep* OR “infantile spasm” OR seizure OR convuls* OR (syndrome W/2 (aicardi OR
angelman OR doose ORdravet OR janz OR jeavons OR “landau kleffner”OR “lennox gastaut” OR ohtahara OR panayiotopoulos OR
rasmussen OR rett OR “sturge weber” OR tassinari OR “unverricht lundborg” OR west)) OR “ring chromosome 20” OR “R20” OR
“myoclonic encephalopathy” OR “pyridoxine dependency”) ANDNOT (TITLE(*eclampsia) OR INDEXTERMS(*eclampsia))) OR
(TITLE-ABS-KEY(lafora* W/4 (disease OR epilep*)) AND NOT (TITLE(dog OR canine) OR INDEXTERMS(dog OR canine))))
AND (TITLE((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR “parallel group” OR crossover OR
“cross over” OR cluster OR “head to head”) PRE/2 (trial OR method OR procedure OR study)) OR ABS((randomiz* OR randomis*
OR controlled OR placebo OR blind* OR unblind* OR “parallel group” OR crossover OR “cross over” OR cluster OR “head to
head”) PRE/2 (trial ORmethod OR procedure OR study)))) ANDNOT (TITLE((adjunct* OR “add-on” OR “add on” OR adjuvant*
OR combination* OR polytherap*) AND NOT (monotherap* OR alone OR singl*)))
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WH A T ’ S N E W
Last assessed as up-to-date: 18 August 2016.
Date Event Description
18 August 2016 New search has been performed Searches updated 18 August 2016; no new studies iden-
tified.
18 August 2016 New citation required but conclusions have not changed Conclusions are unchanged.
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 1, 2003
Date Event Description
22 September 2014 New search has been performed Searches updated 22 September 2014.
22 September 2014 New citation required but conclusions have not
changed
Four new included studies. Conclusions remain un-
changed.
12 August 2009 Amended Copyedits made at editorial base.
24 September 2008 Amended Converted to new review format.
1 October 2006 New search has been performed We re-ran our searches on 1st October 2006; no new
studies were identified
C O N T R I B U T I O N S O F A U T H O R S
• SJ Nolan assessed studies for inclusion in the review update, assessed risk of bias in all included studies, performed analyses in
SAS version 9.2, Stata version 11.2, and MetaView, added survival plots and a ’Summary of findings’ table, and updated the text of
the review under the supervision of C Tudur Smith and AG Marson.
• C Tudur Smith was the lead investigator on the original review, assessed eligibility and methodological quality of original
individual studies, organised and cleaned the IPD sets, performed data validation checks and statistical analyses, and co-wrote the
original review.
• AG Marson obtained IPD from trial investigators, provided guidance with the clinical interpretation of results, assessed
eligibility and methodological quality of individual studies, and co-wrote the original review.
• J Weston independently assessed risk of bias in all included studies.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
December 2014: The title was changed to specify that the review uses individual participant data (IPD).
Update 2015: We added sensitivity analyses following the discovery of inconsistencies between IPD provided and published papers.
The existence of such inconsistencies could not have been known at the time of writing the original protocol.
Update 2015: We added the outcomes ’time to six-month remission’ and ’adverse events’ for consistency with the other reviews in the
series of Cochrane IPD reviews investigating pair-wise monotherapy comparisons.
Update 2016: We added ’Summary of findings’ tables to the update in 2015 and added text in the Methods section for ’Summary of
findings’ tables in August 2016.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [∗therapeutic use]; Carbamazepine [∗therapeutic use]; Epilepsies, Partial [∗drug therapy]; Epilepsy, Generalized [∗drug
therapy]; Epilepsy, Tonic-Clonic [drug therapy]; Phenobarbital [∗therapeutic use]; Randomized Controlled Trials as Topic
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MeSH check words
Adult; Child; Humans
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